PMC:5118426 / 7466-7470 JSON TXT

Bile Acids in Neurodegenerative Disorders Abstract Bile acids, a structurally related group of molecules derived from cholesterol, have a long history as therapeutic agents in medicine, from treatment for primarily ocular diseases in ancient Chinese medicine to modern day use as approved drugs for certain liver diseases. Despite evidence supporting a neuroprotective role in a diverse spectrum of age-related neurodegenerative disorders, including several small pilot clinical trials, little is known about their molecular mechanisms or their physiological roles in the nervous system. We review the data reported for their use as treatments for neurodegenerative diseases and their underlying molecular basis. While data from cellular and animal models and clinical trials support potential efficacy to treat a variety of neurodegenerative disorders, the relevant bile acids, their origin, and the precise molecular mechanism(s) by which they confer neuroprotection are not known delaying translation to the clinical setting. Background Bile acids are a structurally related group of molecules derived from cholesterol that are widely known for their role as chemical detergents involved in the intestinal absorption and transport of fats and lipid-soluble nutrients (Schonewille et al., 2016). However, bile acids also appear to play as yet poorly defined physiological roles in the central nervous system (Lieu et al., 2014). Surprisingly little work has been done on the physiological roles of bile acids in neurons or the central nervous system (Zhang et al., 1997) despite a wide array of data in model systems and despite the significant therapeutic advantages of bile acids. Bile acids are readily bioavailable via oral, subcutaneous, or intravenous administration, can cross the blood-brain barrier, are relatively nontoxic, and have been approved by the U.S. Food and Drug Administration for human therapeutic use. We review evidence supporting a potentially therapeutic role for bile acids in a number of diverse neurodegenerative conditions. A summary of the studies described below is presented in Tables 1, 2. Table 1 Model system and human data implicating bile acids in neurodegenerative disorders. Disease/Phenotype Model Bile acid Mode of administration Dose or concentration Effects References Spinocerebellar ataxia type 1 (SCA1) Transgenic mouse with human ATXN1 with 82 CAG trinucleotide repeats under control of a Purkinje-cell promoter TUDCA Subcutaneous injection 500 mg/kg TUDCA crossed the blood-brain barrier but had no effect on cell survival Kaemmerer et al., 2001 Huntington's disease (HD) 3-nitropropionic acid-treated rat neuronal RN33B cells TUDCA Media 100 μM Decreased apoptosis by preventing mitochondrial depolarization and outer membrane disruption Rodrigues et al., 2000 GUDCA 500 μM UDCA 500 μM HD 3-nitropropionic acid-treated rats TUDCA Intraperitoneal injection 50 mg/kg Decreased apoptosis Keene et al., 2001 Reduced lesion volume Preserved sensorimotor and cognitive function HD R6/2 transgenic mouse with 150 CAG trinucleotide repeats in exon 1 of the huntingtin gene TUDCA Subcutaneous injection 500 mg/kg Reduced striatal cell apoptosis Keene et al., 2002 Decreased levels of intracellular inclusions Improved locomotor and sensorimotor function Parkinson's disease (PD) Sodium nitroprusside-treated human dopaminergic SH-SY5Y cells UDCA Media 50–200 μM Dose dependent inhibition of apoptosis via the PI3K- Chun and Low, 2012 Akt/PKB pathways Reduced ROS and reactive nitrogen species Maintained intracellular GSH levels PD Skin fibroblasts from PD patients UDCA Media 10–100 nM Restored mitochondrial function dependent upon glucocorticoid receptor activation and Akt phosphorylation Mortiboys et al., 2013 PD MPTP-induced mouse model TUDCA Intraperitoneal injection 50 mg/kg Reduction in loss of dopaminergic neurons by preserving levels of phosphorylated JNK, reducing ROS levels, and activating the Akt pathway Castro-Caldas et al., 2012 Alzheimer's disease (AD) Aβ-treated primary rat cortical neurons TUDCA Media 100 μM Decreased nuclear fragmentation and cytochrome c release through the PI3K pathway Solá et al., 2003 AD Aβ-treated mouse BV-2 microglial cells UDCA Media 250 μM Anti-inflammatory effect by inhibiting NF-κB activation Joo et al., 2004 AD Aβ-treated primary rat cortical neurons UDCA TUDCA Media 100 μM Decreased apoptosis dependent on interaction with the mineralocorticoid receptor Sola et al., 2006 AD Double transgenic APP/PS1 mice TUDCA Diet 0.4% wt/wt Reduced amyloid plaque number Nunes et al., 2012; Ramalho et al., 2013 Decreased injury to neurons Improved memory retention Decreased the loss of a postsynaptic marker in the hippocampus Amyotrophic lateral sclerosis (ALS) Mouse NSC-34 cells with the human SOD1G93A mutation GUDCA Media 50 μM Decreased cell death by blocking caspase-9 activation Vaz et al., 2015 ALS Primary mouse ventral midbrain cultures CA Media 10 μM Increased neuronal survival and promoted neurogenesis via LXR Theofilopoulos et al., 2013 ALS Clinical trial with ALS patients UDCA Oral Up to 50 mg/kg UDCA is well tolerated and well absorbed by oral administration Parry et al., 2010 UDCA crosses the blood-brain barrier in a dose-dependent manner ALS Clinical trial with ALS patients UDCA Oral 3.5 g/140 mL/day Slight decrease in progression of ALS but results were inconclusive Min et al., 2012 ALS Clinical trial with ALS patients TUDCA Oral 1 g, twice daily TUDCA is well tolerated Elia et al., 2016 Treatment resulted in improved function and slowed disease progression Prion disease Prion infected male mice UDCA Diet 0.01% wt/wt Reduced astrogliosis Cortez et al., 2015 Prolonged survival Cerebrotendinous xanthomatosis (CTX) Human patients CDCA Oral 15 mg/kg/day Amelioration of neurological symptoms Bjorkhem, 2013 Improved prognosis Retinitis pigmentosa (RP) Homozygous P23H rhodopsin transgenic rats TUDCA Intraperitoneal injection 500 mg/kg Reduced photoreceptor loss Fernandez-Sanchez et al., 2011 Preserved structure, function, and synaptic contacts of rods and cones RP Transgenic rd10 mouse model TUDCA Subcutaneous injection 500 mg/kg Higher cone cell density from decreased apoptosis Preserved structure and function of photoreceptor cells Boatright et al., 2006; Phillips et al., 2008; Oveson et al., 2011 Light-induced retinal degeneration Light-induced retinal damage (LIRD) mouse model TUDCA Subcutaneous injection 500 mg/kg Higher cone cell density from decreased apoptosis Preserved structure and function of photoreceptor cells Boatright et al., 2006; Phillips et al., 2008; Oveson et al., 2011 Leber congenital amaurosis Homozygous LRAT knockout mice TUDCA Subcutaneous injection 500 mg/kg Slowed cone degeneration in the ventral and central retina by preventing apoptosis and increasing ER-associated protein degradation Zhang et al., 2012; Fu and Zhang, 2014 In vitro retinal degeneration Whole mount cat retinas TUDCA Media 0.5 μM Greater receptive field size Xia et al., 2015 Decreased irradiance threshold Maintenance of the contrast threshold Retinal dystrophy Primary human retinal epithelium cells TUDCA Media 100 μM Protective against H2O2-induced impairment of phagocytosis Murase et al., 2015 Retinal detachment Subretinal injection of hyaluronic acid in rats TUDCA Intraperitoneal injection 500 mg/kg Reduced apoptosis in the outer nuclear layer of the retina Mantopoulos et al., 2011 Decreased caspase activation and protein carbonyl production Diabetic retinopathy Primary rat retinal neuron cells exposed to elevated glucose TUDCA Media 100 μM Decreased apoptosis Gaspar et al., 2013 Decreased mito-nuclear translocation of apoptosis-inducing factor (AIF) Decreased ROS and protein carbonyl production Retinal ganglion cell degeneration Intravitreal injection of NMDA in rats TUDCA Intraperitoneal injection 500 mg/kg Increased survival of retinal ganglion cells Gomez-Vicente et al., 2015 Ischemic stroke Middle cerebral artery occlusion in rats TUDCA Intravenous injection 400 mg/kg Reduction in infarct size Rodrigues et al., 2002 Reduced apoptosis Preserved mitochondrial integrity Hemorrhagic stroke Collagenase TUDCA Intra-arterial injection 200 mg/kg Decreased lesion volumes, peri-hematoma apoptosis, caspase activity, NF-κB activiation; increased AKT activation, neurobehavioral improvement Rodrigues et al., 2003 Acute neuroinflammation Intracerebro-ventricular injection with LPS in mice TUDCA Intraperitoneal injection 500 mg/kg Reduced glial cell activation Yanguas-Casás et al., 2014 Acute neuroinflammation Primary cultures of microglial cells and astrocytes from rats treated with LPS and/or IFN-γ TUDCA Media 200 μM Reduced microglial chemotaxis and expression of MCP-1 and VCAM-1 Yanguas-Casás et al., 2014 Sleep-wake pattern Wild type and histamine deficient mice UDCA Diet 32 mg/kg Promotes wakefulness through disinhibition of the histaminergic system via GABAA receptors Yanovsky et al., 2012 Hypothalamic network activity Primary cultures of mouse posterior hypothalamus CA Media Up to 8 mM Reduced firing, synchronized network activity, and blocked GABAA and NMDA receptor activity Schubring et al., 2012 GCA TCA DCA TDCA CDCA GCDCA TCDCA DHCA Neurotransmitter release Sympathetic ganglion neurons isolated from of adult bull frogs CA Media 1 μM Inhibits N-type calcium channel currents Lee et al., 2012 Hyperbilirubinemia Unconjugated bilirubin-treated organotypic-cultured hippocampal slices from rats GUDCA Media 50 mM Decreased cell death, NOS, glutamate release Silva et al., 2012 Glutamate-induced neurotoxicity Glutamate-treated primary rat cortical neurons TUDCA Media 100 μM Decreased apoptosis by activating a PI3K-dependent Bad signaling pathway Castro et al., 2004 Table 2 Genomic and metabolomics data implicating bile acids in neurodegenerative disorders. Disease Approach Genetic association References PD Meta-analysis of GWAS data from PD and normal patients HSD3B7 missense SNP in HSD3B7, Cheng et al., 2003; Song and Lee, 2013 PD Meta-analysis of PD miRNA GWAS data SNPs in a miRNA-binding site in the 3' UTR of HSD3B7 Ghanbari et al., 2016 ALS Peripheral blood cell eQTL of ALS and normal patients CYP27A1 eQTL Diekstra et al., 2012 AD Plasma metabolomic analysis of AD and normal patients Increased plasma GUDCA levels in patients with mild cognitive impairment or AD Mapstone et al., 2014 Biology of bile acids Two aspects of bile acid metabolism are relevant to their role in neurodegenerative disorders, bile acids that circulate systemically and that are synthesized by neurons. Circulating bile acids are largely synthesized from cholesterol in the liver (Prawitt et al., 2011). Ingestion of food causes bile acid secretion from the gallbladder through the common bile duct to the duodenum in order to facilitate the absorption of lipids and lipid-soluble vitamins via formation of micelles. Upon reaching the ileum, bile acids are transported by specific transport proteins to the portal circulation for recycling back to the liver. The process is highly efficient with over 95% of bile acids resorbed, the remaining 5% proceeding to the colon and excreted through the stool. Enterohepatic recycling of the bile acid pool occurs about 12 times per day, thus the net flux of bile acids through primarily the portal, but also the systemic, circulation is substantial. The two primary bile acids produced by the liver in humans are cholic acid (CA) and chenodeoxycholic acid (CDCA). These primary bile acids can undergo conjugation with glycine or taurine prior to secretion in the bile to form glycocholic acid (GCA), taurocholic acid (TCA), glycochenodeoxycholic acid (GCDCA), and taurochenodeoxycholic acid (TCDCA). In the intestine, they can undergo dehydroxylation by gut bacteria to produce deoxycholic acid (DCA) and lithocholic acid (LCA). Further chemical modifications can also occur resulting in other minor species such as ursodeoxycholic acid (UDCA) (Zhang et al., 1997). Bile acids also function as signaling molecules through interaction with several receptor systems (Figure 1). They serve as ligands for the nuclear transcription factor farnesoid X receptor (FXR), which forms a heterodimeric complex with retinoid X receptor α (RXRα) that binds to an inverted repeat sequence in gene promoters (Hoeke et al., 2014). They are also agonists for a cellular receptor, the G protein-coupled bile acid receptor 1 (GPBAR1 or TGR5), to mediate signaling via the generation of cyclic adenosine monophosphate (cAMP) by adenylate cyclase, which stimulates cAMP-dependent protein kinase A (PKA) and phosphorylation of the cAMP response element binding protein (CREB) transcription factor (Hodge and Nunez, 2016; Schonewille et al., 2016). Figure 1 Despite documented neuroprotective roles in models of neurodegenerative disorders, the primary signaling pathways (TGR5 and FXR) and the potential role of endogenous bile acids have not yet been studied. Alzheimer's disease Alzheimer's disease (AD) is characterized by dementia and memory loss that is associated with extracellular senile plaques of amyloid precursor protein derived amyloid-beta (Aβ) protein and intracellular neurofibrillary tangles consisting of the Tau protein (Scheltens et al., 2016). A primary in vitro model of AD is therefore treatment of cells with Aβ peptide that causes cytotoxicity to both primary cultures of neurons as well as neuronal cell lines. Treatment of primary cortical neuron cultures derived from Wistar rat embryos with tauroursodeoxycholic acid (TUDCA) prior to exposure to Aβ peptide significantly decreased nuclear fragmentation and cytochrome c release that was dependent upon activation of the PI3K pathway (Solá et al., 2003). The bile acid UDCA was found to regulate IκBα and NF-κB regulated genes in the mechanism of protection against Aβ toxicity in the BV-2 microglial cell line (Joo et al., 2004). Certain steroid hormones exhibit neuroprotective properties that are thought to be mediated in part through interaction with nuclear steroid receptors, including the glucocorticoid, and mineralocorticoid receptors (Garcia-Segura and Balthazart, 2009). Neurosteroids and bile acids are cholesterol derivatives that share some structural similarity so certain bile acids are natural ligands for these receptors. UDCA and TUDCA reduced Aβ induced apoptosis of primary rat cortical neurons that was found to be dependent upon the mineralocorticoid but not the glucocorticoid receptor (Sola et al., 2006). TUDCA appeared to interact with the ligand binding domain of the mineralocorticoid receptor to prevent its binding to heat shock protein 90 and subsequent trafficking for proteosomal processing allowing for translocation to the nucleus. Bile acids have also been studied in animal models of AD. In double transgenic mice (APP/PS1) that express human amyloid precursor protein carrying the KM670/671NL Swedish double mutation and the human presenilin 1 L166P mutation under the regulation of a neuron-specific promoter, treatment via dietary supplementation of standard laboratory chow with 0.4% (wt/wt) of TUDCA significantly reduced amyloid plaque number in the frontal cortex and hippocampus, decreased injury to neurons measured by determining loss of, or damage to, neuronal fibers surrounding plaques, and improved memory retention measured via contextual, though not auditory, fear conditioning (Nunes et al., 2012) as well as reduced hippocampal and prefrontal amyloid deposition (Lo et al., 2013). TUDCA has also been shown to help preserve the postsynaptic marker postsynaptic density-95 in the hippocampus of APP/PS1 mice (Ramalho et al., 2013). Repurposed RXR agonists or “rexinoids” have also shown some effectiveness in transgenic models of AD (Koster et al., 2016), suggesting a possible involvement of bile acids. In humans, a recent study of cognitively intact patients identified and validated a set of blood-based biomarkers that included glycoursodeoxycholic acid (GUDCA) that could predict the onset of either AD or amnestic mild cognitive impairment, considered an early precursor of AD, within 2–3 years with an accuracy of over 90% (Mapstone et al., 2014). This suggests a potential association of bile acids in the progression or preclinical neurodegenerative phase of AD. Parkinson's disease The effects of bile acids on chemical and genetic models of Parkinson's disease (PD), which is characterized by the selective loss of dopaminergic neurons in the substantia nigra region of the brain and a resulting tremor, have been reported. Sodium nitroprusside (SNP)-induced cytotoxicity of human dopaminergic SH-SY5Y cells has been used as a model of PD. UDCA was found to dose-dependently (50–200 μM) decrease SNP-related cell death. UDCA reduced reactive oxygen species (ROS), reactive nitrogen species (peroxynitrite and nitric oxide), and helped to maintain intracellular glutathione (GSH) levels. Apoptosis markers including nuclear fragmentation, caspase activation, and cytochrome c release were correspondingly reduced. Inhibiting phosphatidylinositiol-3-kinase (PI3K) and Akt/PKB blocked the favorable effects of UDCA on SNP-induced cytotoxic cell death (Chun and Low, 2012). Bile acids have also been implicated in PD through genetic association studies. In a meta-analysis of genome-wide association study (GWAS) data based on the genotypes of 2,525,705 SNPs in 4238 PD cases and 4239 non-PD controls, a total of 3 SNPs were found to be statistically associated with PD, including a non-synonymous missense variant in HSD3B7 (hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7) (Song and Lee, 2013). Recessive mutations in HSD3B7, which catalyzes the second step in the classical pathway of bile acid synthesis, are associated with loss of bile acid synthetic capability and progressive liver disease (Cheng et al., 2003). In a GWAS of 48,844 SNPs residing in miRNA-binding site variants, 32 SNPs were associated with PD that were located in the 3′ untranslated regions of 13 genes including HSD3B7 (Ghanbari et al., 2016), providing further genetic evidence for a role of bile acids in PD. Mitochondrial dysfunction has been associated with PD (Luo et al., 2015). To identify compounds that could restore mitochondrial function in skin fibroblasts obtained from patients with a PD parkin (PARK2) gene mutation, a 2000 compound library was screened for significant improvement in mitochondrial membrane potential (Mortiboys et al., 2013). Ursocholanic acid and the related compound dehydro(11,12)ursolic acid lactone were among the top 15 compounds that had dose response characteristics favorable for drug development and lacked many of the disadvantages of the other top hits. The structurally related bile acid UDCA was also found to rescue mitochondrial function to a similar extent, which was dependent upon activation of the glucocorticoid receptor and increased phosphorylation of Akt. UDCA was also found to restore mitochondrial function in fibroblasts obtained from a PD patient with a LRRK2-G2019S mutation. The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin is a widely used toxin model for PD, replicating most of the clinical and pathological features of PD in humans and animal models. TUDCA was found to play a role in ameliorating neurodegeneration in MPTP-induced degeneration of dopaminergic neurons in the nigrostriatal axis in C57BL/6 glutathione S-transferase pi (GSTP) null mice (Castro-Caldas et al., 2012). Treatment of mice with TUDCA prior to MPTP caused a 30% reduction in loss of dopaminergic neurons and reduced dopaminergic fiber loss. MPTP toxicity has also been associated with increased ROS production and activation of JNK-mediated apoptosis (Huang et al., 2016). TUDCA reduced levels of ROS and preserved levels of phosphorylated JNK (p-JNK) (Castro-Caldas et al., 2012). Amyotrophic lateral sclerosis The loss of motor neurons in Amyotrophic lateral sclerosis (ALS) has prompted therapeutic strategies aimed at preventing neuronal cell death and promoting regeneration (Carvalho et al., 2015). NSC-34 cells, created by fusion of cultured neuroblastoma cells and motor neurons from mouse spinal cord, can be treated with retinoic acid to induce neurite outgrowth and functional characteristics of motor neurons and are considered a highly stable and widely used murine motor neuron cell line model (Maier et al., 2013; Veyrat-Durebex et al., 2014). NSC-34 cells modified to carry the human form of SOD1 with the G93A mutation (hSOD1G93A) have thus been used as a model for ALS. GUDCA was reported to reduce cell death in the NSC-34 hSOD1G93A cell model and to block caspase-9 activation (Vaz et al., 2015). Bile acids also appear to have physiological roles in the central nervous system. CA, a bile acid present in the adult brain, was identified by LC/MS as a ligand of liver X receptor (LXR), activating LXR but not FXR in ventral midbrain dopaminergic neurons (Theofilopoulos et al., 2013). 6α-hydroxylated bile acids and the synthetic bile acid ligand GW3965 were also highly potent activators of LXR. Male LXR knockout mice develop an adult-onset motor neuron degeneration that is associated with impairment of motor coordination, axonal atrophy, astrogliosis, accumulation of lipid and loss of motor neurons in the spinal cord, findings similar to the neuropathology of ALS (Andersson et al., 2005). Additionally, FXR has been shown to contribute to normal motor function in mice (Huang et al., 2015). Several clinical trials of bile acids have been conducted in ALS patients in which evidence for safety and potential efficacy was observed (Parry et al., 2010; Min et al., 2012; Elia et al., 2016). In an ALS clinical trial with orally administered UDCA, the bile acid was found to be well tolerated and crossed into the cerebrospinal fluid in a dose-dependent manner (Parry et al., 2010). In a separate clinical trial to test the efficacy of UDCA for treating ALS patients, oral solubilized administration for 3 months was shown to be well tolerated and there was a slight decrease in the progression of ALS in the treatment group as compared to the placebo group (Min et al., 2012). However, due to the small size of the study and the high rate of patient dropout, the efficacy of the treatment was inconclusive. TUDCA administered orally twice per day for over 1 year resulted in a higher percentage of subjects achieving at least a 15% improvement in the ALS Functional Rating Scale Revised (ALSFRS-R) slope (Elia et al., 2016). Genetic data also implicates bile acid metabolism in ALS. Gene expression profiles obtained from the peripheral blood cells of sporadic ALS patients and normal controls were analyzed in the context of genome-wide SNP genotype data to identify expression quantitative trait loci (eQTLs). A cluster of transcript-SNP pairs with the highest level of statistical significance and meeting correction for multiple testing was associated with CYP27A1 expression in ALS (Diekstra et al., 2012). CYP27A1 is a key enzyme in the alternative bile acid synthesis pathway, and mutations in this enzyme can cause cerebrotendinous xanthomatosis as described below. Huntington's disease Huntington's disease (HD), an autosomal dominantly inherited neurodegenerative disease, is caused by an expansion mutation in CAG triplet repeat number in exon 1 of the huntingtin (HTT) gene (Ross et al., 2014). It is characterized by involuntary choreic movements, psychiatric and behavioral disturbances, and impaired cognitive function. Genetic and chemical animal and cellular models have been developed in which the effects of bile acids have been assessed. For example, 3-nitropropionic acid, an irreversible chemical inhibitor of mitochondrial succinate dehydrogenase, can be used to induce apoptosis of cells in culture and in neurons in the striatum region of the brain that causes changes similar to the morphology and neurochemical changes of HD. Incubation of rat neuronal RN33B cells with TUDCA was found to reduce 3-nitropropionic acid induced apoptosis by about 80% (Rodrigues et al., 2000). Other bile acids, including UDCA and GUDCA, were also associated with decreased apoptosis, preventing 3-nitropropionic acid induced release of mitochondrial cytochrome c, and associated morphological changes in both isolated mitochondria and in intact cells. In rats treated with TUDCA, a similar level of reduction in apoptosis and in the volume of lesions associated with administration of 3-nitropropionic acid was observed that was correlated with preservation of sensorimotor function and performance in cognitive task assays (Keene et al., 2001). These results suggest that the mechanisms of bile acid protection may be similar both in vitro and in vivo. Genetic models of HD have also been studied, including the R6/2 mouse, which is transgenic for a 150 repeat trinucleotide CAG expansion in exon 1 of HTT and manifests severe neurodegeneration, neuronal intranuclear inclusions, and sensorimotor deficits that result in a severely shortened survival of less than 4 months of age (Mangiarini et al., 1996; Davies et al., 1997). TUDCA treatment was administered to the R6/2 transgenic mice subcutaneously at a dose of 500 mg/kg once every 3 days from weaning to 6 months of age, which was tolerated without skin reaction or other effects. The subcutaneously administered TUDCA was absorbed into the circulation, crossed the blood-brain barrier, and produced seven-fold increases in UDCA levels in the brain without evidence of adverse effects. TUDCA treatment resulted in significantly reduced striatal cell apoptosis, decreased levels of intracellular inclusions, and improved locomotor open field and sensorimotor Rota-Rod performances (Keene et al., 2002). Spinocerebellar ataxia type 1 Spinocerebellar ataxia type 1 (SCA1) is another dominantly inherited neurodegenerative disorder characterized chiefly by progressive ataxia (Meera et al., 2016). SCA1 is caused by expansion of an unstable CAG trinucleotide repeat that encodes a glutamine tract in the Ataxin-1 gene (ATXN1). The disorder is characterized primarily by degeneration of Purkinje neurons of the cerebellum. TUDCA treatment was used to determine whether the survival of Purkinje cells and the onset and progression of ataxia was altered in a transgenic mouse model of SCA1, in which 30 copies of the human ATXN1 cDNA containing a CAG trinucleotide repeat of 82 repeats was under the control of the Pcp-2 Purkinje-cell specific promoter l (Kaemmerer et al., 2001). Despite the successful administration of TUDCA using a similar subcutaneous injection protocol as described above for the R6/2 transgenic HD mouse, and documentation of increased levels in the brain, no effects on cell survival or on the neurological phenotype were noted. The disparate effects in two different genetic models of neurodegenerative disease, suggest that bile acids target specific pathways. Prion diseases Neurodegenerative disorders caused by prions include Creutzfeldt-Jakob disease and similar disorders in animals such as bovine spongiform encephalopathy in cows, chronic wasting disease in deer, and scrapie in sheep (Imran and Mahmood, 2011; Windl and Dawson, 2012). Prion protein (PrPC) is a normal cellular protein that when mutated becomes misfolded (PrPSc). PrPSc can then convert normally folded PrPC to the misfolded form. Accumulation of PrPSc causes loss of neurons, astrogliosis, and spongiform degeneration resulting in dementia, ataxia, and death. One approach to therapeutic development has been to block or interfere with the conversion of PrPC to PrPSc. TUDCA and UDCA were found to substantially reduce this conversion in cell-free aggregation assays as well as in both chronically and acutely infected mouse ScN2a neuroblastoma cells (Cortez et al., 2015). TUDCA and UDCA also reduced neuronal loss in a prion organotypic slice culture model of intracerebral infection that assesses prion replication occurring ex vivo through infection of brain slices with prion infected brain homogenate. UDCA treatment also reduced astrocytosis and prolonged survival in prion infected male C57BL/6 mice, although whether bile acids interacted with the PrPC to PrPSc conversion or mediated protective effects through some other mechanism is not known. Cerebrotendinous xanthomatosis Cerebrotendinous xanthomatosis (CTX) is a very rare autosomal recessive disorder caused by mutations in the CYP27A1 gene (Björkhem and Hansson, 2010; Bjorkhem, 2013). These mutations lead to deficiency of the sterol 27-hydroxylase inner mitochondrial membrane protein. Sterol 27-hydroxylase oxidizes cholesterol to 27-hydroxycholesterol in the alternative bile acid synthesis pathway that leads to the generation of CDCA. Sterol 27-hydroxylase deficiency leads to a reduction of CDCA and upregulation of cholesterol 7α-hydroxylase (CYP7A1), the rate-limiting enzyme in the classic bile acid synthesis pathway resulting in elevated levels of cholestanol and bile alcohols. CTX patients have a mean age of diagnosis of 35 years and manifest multiple neurologic symptoms including dementia, ataxia, peripheral neuropathy, epilepsy, myopathy, and psychiatric disorders, as well as a variety of non-neurological manifestations including premature atherosclerosis, tendon xanthomas, juvenile onset cataracts, osteoporosis, and mild pulmonary insufficiency. Long-term treatment with CDCA can result in amelioration of neurological symptoms and an improved prognosis. Retinal diseases Bear bile has been used in Chinese medicine for several millennia to treat visual disorders (Boatright et al., 2006). This has led to a number of studies investigating the primary constituent of bear bile, TUDCA, as a potential therapeutic agent for several ophthalmological diseases (Boatright et al., 2009). TUDCA has been investigated in retinitis pigmentosa, a heterogeneous group of disorders of retinal degeneration in which progressive peripheral and night vision loss occurs, with central vision impairment. Mutations in about 200 genes, including the gene encoding rhodopsin (RHO), have been identified that cause apoptosis of photoreceptor cells (Daiger et al., 2013). The RHO P23H mutation is the most common cause of retinitis pigmentosa in the United States that is thought to produce structurally altered folding with retention in the endoplasmic reticulum and resulting cytotoxicity. TUDCA administered intraperitoneally once a week from weaning until 4 months of age to homozygous P23H line-3 rats reduced photoreceptor loss across the retina and preserved synapses between photoreceptors and bipolar or horizontal cells (Fernandez-Sanchez et al., 2011). In the rd10 mouse model of retinitis pigmentosa, in which the mice carry a missense mutation in exon 7 of the Pde6b gene resulting in rod photoreceptor cell death within a month after birth, subcutaneous administration of TUDCA resulted in higher cone cell density in all 4 quadrants of the retina (Oveson et al., 2011). TUDCA also decreased apoptosis, preserved the normal retinal photoreceptor cellular architecture, and maintained amplitudes of dark-adapted electroretinogram a- and b-waves (Boatright et al., 2006), even at later stages of severe photoreceptor loss (Phillips et al., 2008). Mutations in the retinoid isomerase (RPE65) or lecithin-retinol acyltransferase (LRAT) genes underlie Leber congenital amaurosis (den Hollander et al., 2008). LRAT is involved in 11-cis retinal recycling in the retinal pigment epithelium through mediating the esterification of all-trans retinol to all-trans retinyl esters, which are the substrates for RPE65. Homozygous Lrat knockout mice that were subcutaneously administered TUDCA every 3 days from 1 to 4 weeks after birth had about a three-fold increase in cone density in the ventral and central retina and increased ER-associated protein degradation (Zhang et al., 2012; Fu and Zhang, 2014). Twice per week subcutaneous injections of TUDCA also preserved ERG b-waves and the outer nuclear layer of the retina in Bardet-Biedl syndrome type 1 mice (Bbs1M390R/M390R), another model for retinal degeneration (Drack et al., 2012). TUDCA ameliorated cell death and loss of photoreceptor function after exposure to high levels of light (10,000 lux) that can induce retinal degeneration in albino Balb/C mice (Boatright et al., 2006). TUDCA pre-treatment of ex vivo perfused whole mount feline retinas repeatedly exposed to light stimulation and dark adaptations over 5 h resulted in greater receptive field size, decreased irradiance threshold, and maintenance of the contrast threshold (Xia et al., 2015). Retinal dystrophy can be caused by defects in the phagocytosis by retinal pigment epithelium cells of the photoreceptor outer segments that are shed, a continuous and extremely active process involving thousands of shed membranous disks each day. TUDCA was found to increase phagocytic activity and inhibit hydrogen peroxide induced impairment of phagocytosis by both cultured ARPE-19 cells and primary human retinal pigment epithelium cells (Murase et al., 2015). The phosphorylation of MerTK was significantly increased by TUDCA in a concentration-dependent manner but did not affect expression of the ER stress marker glucose regulated protein-78 (GRP-78). Bile acids also had an effect in ameliorating cell death in a model of retinal detachment via intraperitoneal injection of TUDCA at 3 and 5 days post detachment, times when acute photoreceptor loss occurs in the outer nuclear layer of the retina (Mantopoulos et al., 2011). TUDCA treatment also blocked the production of protein carbonyls with decreased caspase activation but did not decrease endoplasmic reticulum (ER) stress. In a diabetic retinopathy model, TUDCA significantly decreased apoptosis measured by TUNEL assay of primary rat retinal neural cells exposed to 30 mM glucose concentration, which causes caspase-independent cell death (Gaspar et al., 2013). TUDCA also decreased the amount of apoptosis-inducing factor (AIF) released from the mitochondria and its subsequent accumulation in the nucleus. Production of protein carbonyls and ROS were also significantly decreased after TUDCA treatment. Over-stimulation of N-methyl-D-aspartate (NMDA) receptors, one of three ionotropic glutamate receptor subtypes that are expressed in inner retinal cells, by intravitreal injection of NMDA has frequently been used to model the cell death pathway that occurs in retinal diseases such as glaucoma (Danesh-Meyer, 2011). This model of excitotoxicity causes disruption of sodium-potassium balance, calcium overload, mitochondrial dysfunction, and oxidative stress (Gomez-Vicente et al., 2015). In mice, administration of TUDCA prior to the intravitreal injection of NMDA was found to increase survival of retinal ganglion cells. Acute stroke, spinal cord injury, and neuropathy A single intravenous (i.v.) dose of TUDCA administered to rats 60 min after occlusion of the middle cerebral artery markedly reduced infarct size and apoptosis and preserved mitochondrial integrity (Rodrigues et al., 2002). The single i.v. dose resulted in a significant increase in brain UDCA levels from near undetectable levels to 0.15 nmol/g. TUDCA was also found to have an anti-inflammatory effect in the context of the central nervous system. TUDCA reduced glial cell activation and microglial chemotaxis and reduced expression of the MCP-1 chemoattractant and vascular adhesion proteins such as VCAM-1 in microglial cells and astrocytes treated with either interferon gamma (IFN-γ) or lipopolysaccharide and IFN-γ (Yanguas-Casás et al., 2014). Injection of TUDCA into the carotid artery 1 h prior to or up to 6 h after collagenase injection into the striatum to induce hemorrhagic lesions decreased lesion volumes, peri-hematoma apoptosis, and caspase activity at 2 days by about 50%, as well as decreased NF-κB and increased AKT activation that was associated with neurobehavioral improvement (Rodrigues et al., 2003). TUDCA injected intraperitoneally 1 min after spinal cord crush injury decreased apoptosis and corresponding tissue injury (Colak et al., 2008). In a phase II open-label study of oral doxycycline and TUDCA taken three times/day for 1 year in patients with transthyretin amyloidosis (ATTR), progression of neuropathy was stabilized (Obici et al., 2012). Modulation of neurotransmitter activity The wake period of normal mice was found to be increased with administration of UDCA that also decreased slow wave sleep (Yanovsky et al., 2012). In contrast, administration of UDCA to histidine decarboxylase knockout mice, that are deficient in histamine that stimulates arousal, decreased wakefulness and altered cortical EEG and sleep-wake parameters. Using in vitro patch-clamp recordings from histaminergic neurons, UDCA was found to inhibit GABAergic currents and to serve as an antagonist for GABAA receptors expressed in HEK293 cells. In one of the few studies to analyze more than one or two bile acids, a structure-function relationship analysis was performed using cultured hypothalamic neurons (Schubring et al., 2012). Bile acids were found to modulate firing frequency and synchrony, and to block activity of GABAA and NMDA receptors. Antagonist activity for both the GABAA and NMDA receptors was strongest for CDCA followed by DCA, CA, and dehydrocholate. Involvement of bile acid binding to TGR5 was excluded as a potential mechanism in the neurotransmitter receptor blockade (Keitel et al., 2010). CA was found to serve as an inhibiter for N-type Ca2+ channel currents of neurons isolated from the caudal paravertebral sympathetic ganglia of adult bull frogs (Rana catesbeiana), although open and shut times, slope conductance, and single channel current amplitude, were not significantly affected (Lee et al., 2012). Overstimulation of glutamate receptors to induce excitotoxicity in neurons isolated from late stage fetal rat brains was largely suppressed by GUDCA. This bile acid appeared to suppress glutamate release in either normal or microglia-depleted hippocampal tissue slices (Silva et al., 2012). Pretreatment of primary cultures of fetal rat cortical neurons with TUDCA significantly reduced glutamate excitotoxicity associated cell death. TUDCA treatment resulted in phosphorylation and translocation of the pro-apoptotic Bad protein from the mitochondria to the cytosol. Inhibiting the PI3K signaling pathway blocked the anti-apoptotic effects of TUDCA (Castro et al., 2004). Potential as neurotrophic factors Neurotrophic factors are classified primarily as proteins that bind to receptors, e.g., tropomyosin related kinase receptors TrkA, TrkB, and TrkC and p75 neurotrophin receptor (p75NTR) that can modulate Trk activation, to activate signaling pathways that promote neuronal growth and survival (Rodrigues et al., 2014). Several molecules have been identified as neurotrophic factors, including brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), and glial cell-line-derived neurotrophic factor (GDNF) that can stimulate the growth and differentiation of neuronal cells, as well as prevent cell death. Despite the therapeutic promise of such neurotrophic factors for treating neurodegenerative disorders (Tovar-Y-Romo et al., 2014), their limited bioavailability presents a major roadblock. Mimetics with more favorable bioavailability profiles have therefore been pursued (Tiwari and Chaturvedi, 2014), as well as investigation of proneurogenic peptides and small molecules that exhibit neuroprotective properties (Airavaara et al., 2012), including retinoic acid (Malik et al., 2000; Riancho et al., 2016). Retinoic acid shares a common role in regulating lipid homeostasis with bile acids, whose cognate receptor FXR can form heterodimers with RXRα. Thus, retinoic acid may activate the FXR signaling pathway and vice versa (Yang et al., 2014). Whether bile acids mediate effects in the nervous system through a similar mechanism is not known (Figure 1). Conclusions and outlook Neuroprotective effects of several bile acids are well documented in a wide range of neurodegenerative diseases, including AD, PD, ALS, HD, and retinal degeneration, in cellular and animal models and in human clinical trials. Due to the historical precedent set by the use of bear bile in ancient Chinese medicine, the majority of the studies have focused on UDCA and its derivatives. However, bile acids are a relatively large group of structurally related molecules, thus little is known about the potential efficacy of other bile acid species or the roles of circulating vs. endogenous bile acids synthesized within the central nervous system. In addition, most of the mechanistic studies have been centered on apoptosis and related pathways (Figure 2). However, essentially no data is available on the primary signaling pathways through which bile acids act, the cellular receptor TGR5 and the nuclear receptors FXR and RXRα, despite the well-known function of retinoic acid as a potent neurotrophic molecule. Determining the precise molecular mechanism(s) of neuroprotection by bile acids in neurodegenerative disorders will be important to realize their future therapeutic potential. Figure 2 Molecular pathways implicated in the neuroprotective effects of bile acids in neurodegenerative disease models. Despite the relatively large structurally related group of bile acids, relatively few have been studied in neurodegenerative disorders. A major focus has been on apoptotic pathways and the PI3 kinase and AKT signaling pathway. Surprisingly, the primary signaling pathways through which bile acids act, TGR5, FXR, and FXR/RXR have received essentially no attention (designated by “?”), despite that retinoic acid is known to be a potent neurotrophic molecule. Author contributions GG and HA designed, wrote, revised, and edited the manuscript. Both authors approved the submitted version of the manuscript. Funding This work was funded by the Lewis Katz School of Medicine at Temple University Department of Medical Genetics and Molecular Biochemistry and the Joseph & Rebecca Goodfriend Endowed Chair in Genetics. Conflict of interest statement The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Document structure show

article-title	Bile Acids in Neurodegenerative Disorders
abstract	Bile acids, a structurally related group of molecules derived from cholesterol, have a long history as therapeutic agents in medicine, from treatment for primarily ocular diseases in ancient Chinese medicine to modern day use as approved drugs for certain liver diseases. Despite evidence supporting a neuroprotective role in a diverse spectrum of age-related neurodegenerative disorders, including several small pilot clinical trials, little is known about their molecular mechanisms or their physiological roles in the nervous system. We review the data reported for their use as treatments for neurodegenerative diseases and their underlying molecular basis. While data from cellular and animal models and clinical trials support potential efficacy to treat a variety of neurodegenerative disorders, the relevant bile acids, their origin, and the precise molecular mechanism(s) by which they confer neuroprotection are not known delaying translation to the clinical setting.
p	Bile acids, a structurally related group of molecules derived from cholesterol, have a long history as therapeutic agents in medicine, from treatment for primarily ocular diseases in ancient Chinese medicine to modern day use as approved drugs for certain liver diseases. Despite evidence supporting a neuroprotective role in a diverse spectrum of age-related neurodegenerative disorders, including several small pilot clinical trials, little is known about their molecular mechanisms or their physiological roles in the nervous system. We review the data reported for their use as treatments for neurodegenerative diseases and their underlying molecular basis. While data from cellular and animal models and clinical trials support potential efficacy to treat a variety of neurodegenerative disorders, the relevant bile acids, their origin, and the precise molecular mechanism(s) by which they confer neuroprotection are not known delaying translation to the clinical setting.
body	Background Bile acids are a structurally related group of molecules derived from cholesterol that are widely known for their role as chemical detergents involved in the intestinal absorption and transport of fats and lipid-soluble nutrients (Schonewille et al., 2016). However, bile acids also appear to play as yet poorly defined physiological roles in the central nervous system (Lieu et al., 2014). Surprisingly little work has been done on the physiological roles of bile acids in neurons or the central nervous system (Zhang et al., 1997) despite a wide array of data in model systems and despite the significant therapeutic advantages of bile acids. Bile acids are readily bioavailable via oral, subcutaneous, or intravenous administration, can cross the blood-brain barrier, are relatively nontoxic, and have been approved by the U.S. Food and Drug Administration for human therapeutic use. We review evidence supporting a potentially therapeutic role for bile acids in a number of diverse neurodegenerative conditions. A summary of the studies described below is presented in Tables 1, 2. Table 1 Model system and human data implicating bile acids in neurodegenerative disorders. Disease/Phenotype Model Bile acid Mode of administration Dose or concentration Effects References Spinocerebellar ataxia type 1 (SCA1) Transgenic mouse with human ATXN1 with 82 CAG trinucleotide repeats under control of a Purkinje-cell promoter TUDCA Subcutaneous injection 500 mg/kg TUDCA crossed the blood-brain barrier but had no effect on cell survival Kaemmerer et al., 2001 Huntington's disease (HD) 3-nitropropionic acid-treated rat neuronal RN33B cells TUDCA Media 100 μM Decreased apoptosis by preventing mitochondrial depolarization and outer membrane disruption Rodrigues et al., 2000 GUDCA 500 μM UDCA 500 μM HD 3-nitropropionic acid-treated rats TUDCA Intraperitoneal injection 50 mg/kg Decreased apoptosis Keene et al., 2001 Reduced lesion volume Preserved sensorimotor and cognitive function HD R6/2 transgenic mouse with 150 CAG trinucleotide repeats in exon 1 of the huntingtin gene TUDCA Subcutaneous injection 500 mg/kg Reduced striatal cell apoptosis Keene et al., 2002 Decreased levels of intracellular inclusions Improved locomotor and sensorimotor function Parkinson's disease (PD) Sodium nitroprusside-treated human dopaminergic SH-SY5Y cells UDCA Media 50–200 μM Dose dependent inhibition of apoptosis via the PI3K- Chun and Low, 2012 Akt/PKB pathways Reduced ROS and reactive nitrogen species Maintained intracellular GSH levels PD Skin fibroblasts from PD patients UDCA Media 10–100 nM Restored mitochondrial function dependent upon glucocorticoid receptor activation and Akt phosphorylation Mortiboys et al., 2013 PD MPTP-induced mouse model TUDCA Intraperitoneal injection 50 mg/kg Reduction in loss of dopaminergic neurons by preserving levels of phosphorylated JNK, reducing ROS levels, and activating the Akt pathway Castro-Caldas et al., 2012 Alzheimer's disease (AD) Aβ-treated primary rat cortical neurons TUDCA Media 100 μM Decreased nuclear fragmentation and cytochrome c release through the PI3K pathway Solá et al., 2003 AD Aβ-treated mouse BV-2 microglial cells UDCA Media 250 μM Anti-inflammatory effect by inhibiting NF-κB activation Joo et al., 2004 AD Aβ-treated primary rat cortical neurons UDCA TUDCA Media 100 μM Decreased apoptosis dependent on interaction with the mineralocorticoid receptor Sola et al., 2006 AD Double transgenic APP/PS1 mice TUDCA Diet 0.4% wt/wt Reduced amyloid plaque number Nunes et al., 2012; Ramalho et al., 2013 Decreased injury to neurons Improved memory retention Decreased the loss of a postsynaptic marker in the hippocampus Amyotrophic lateral sclerosis (ALS) Mouse NSC-34 cells with the human SOD1G93A mutation GUDCA Media 50 μM Decreased cell death by blocking caspase-9 activation Vaz et al., 2015 ALS Primary mouse ventral midbrain cultures CA Media 10 μM Increased neuronal survival and promoted neurogenesis via LXR Theofilopoulos et al., 2013 ALS Clinical trial with ALS patients UDCA Oral Up to 50 mg/kg UDCA is well tolerated and well absorbed by oral administration Parry et al., 2010 UDCA crosses the blood-brain barrier in a dose-dependent manner ALS Clinical trial with ALS patients UDCA Oral 3.5 g/140 mL/day Slight decrease in progression of ALS but results were inconclusive Min et al., 2012 ALS Clinical trial with ALS patients TUDCA Oral 1 g, twice daily TUDCA is well tolerated Elia et al., 2016 Treatment resulted in improved function and slowed disease progression Prion disease Prion infected male mice UDCA Diet 0.01% wt/wt Reduced astrogliosis Cortez et al., 2015 Prolonged survival Cerebrotendinous xanthomatosis (CTX) Human patients CDCA Oral 15 mg/kg/day Amelioration of neurological symptoms Bjorkhem, 2013 Improved prognosis Retinitis pigmentosa (RP) Homozygous P23H rhodopsin transgenic rats TUDCA Intraperitoneal injection 500 mg/kg Reduced photoreceptor loss Fernandez-Sanchez et al., 2011 Preserved structure, function, and synaptic contacts of rods and cones RP Transgenic rd10 mouse model TUDCA Subcutaneous injection 500 mg/kg Higher cone cell density from decreased apoptosis Preserved structure and function of photoreceptor cells Boatright et al., 2006; Phillips et al., 2008; Oveson et al., 2011 Light-induced retinal degeneration Light-induced retinal damage (LIRD) mouse model TUDCA Subcutaneous injection 500 mg/kg Higher cone cell density from decreased apoptosis Preserved structure and function of photoreceptor cells Boatright et al., 2006; Phillips et al., 2008; Oveson et al., 2011 Leber congenital amaurosis Homozygous LRAT knockout mice TUDCA Subcutaneous injection 500 mg/kg Slowed cone degeneration in the ventral and central retina by preventing apoptosis and increasing ER-associated protein degradation Zhang et al., 2012; Fu and Zhang, 2014 In vitro retinal degeneration Whole mount cat retinas TUDCA Media 0.5 μM Greater receptive field size Xia et al., 2015 Decreased irradiance threshold Maintenance of the contrast threshold Retinal dystrophy Primary human retinal epithelium cells TUDCA Media 100 μM Protective against H2O2-induced impairment of phagocytosis Murase et al., 2015 Retinal detachment Subretinal injection of hyaluronic acid in rats TUDCA Intraperitoneal injection 500 mg/kg Reduced apoptosis in the outer nuclear layer of the retina Mantopoulos et al., 2011 Decreased caspase activation and protein carbonyl production Diabetic retinopathy Primary rat retinal neuron cells exposed to elevated glucose TUDCA Media 100 μM Decreased apoptosis Gaspar et al., 2013 Decreased mito-nuclear translocation of apoptosis-inducing factor (AIF) Decreased ROS and protein carbonyl production Retinal ganglion cell degeneration Intravitreal injection of NMDA in rats TUDCA Intraperitoneal injection 500 mg/kg Increased survival of retinal ganglion cells Gomez-Vicente et al., 2015 Ischemic stroke Middle cerebral artery occlusion in rats TUDCA Intravenous injection 400 mg/kg Reduction in infarct size Rodrigues et al., 2002 Reduced apoptosis Preserved mitochondrial integrity Hemorrhagic stroke Collagenase TUDCA Intra-arterial injection 200 mg/kg Decreased lesion volumes, peri-hematoma apoptosis, caspase activity, NF-κB activiation; increased AKT activation, neurobehavioral improvement Rodrigues et al., 2003 Acute neuroinflammation Intracerebro-ventricular injection with LPS in mice TUDCA Intraperitoneal injection 500 mg/kg Reduced glial cell activation Yanguas-Casás et al., 2014 Acute neuroinflammation Primary cultures of microglial cells and astrocytes from rats treated with LPS and/or IFN-γ TUDCA Media 200 μM Reduced microglial chemotaxis and expression of MCP-1 and VCAM-1 Yanguas-Casás et al., 2014 Sleep-wake pattern Wild type and histamine deficient mice UDCA Diet 32 mg/kg Promotes wakefulness through disinhibition of the histaminergic system via GABAA receptors Yanovsky et al., 2012 Hypothalamic network activity Primary cultures of mouse posterior hypothalamus CA Media Up to 8 mM Reduced firing, synchronized network activity, and blocked GABAA and NMDA receptor activity Schubring et al., 2012 GCA TCA DCA TDCA CDCA GCDCA TCDCA DHCA Neurotransmitter release Sympathetic ganglion neurons isolated from of adult bull frogs CA Media 1 μM Inhibits N-type calcium channel currents Lee et al., 2012 Hyperbilirubinemia Unconjugated bilirubin-treated organotypic-cultured hippocampal slices from rats GUDCA Media 50 mM Decreased cell death, NOS, glutamate release Silva et al., 2012 Glutamate-induced neurotoxicity Glutamate-treated primary rat cortical neurons TUDCA Media 100 μM Decreased apoptosis by activating a PI3K-dependent Bad signaling pathway Castro et al., 2004 Table 2 Genomic and metabolomics data implicating bile acids in neurodegenerative disorders. Disease Approach Genetic association References PD Meta-analysis of GWAS data from PD and normal patients HSD3B7 missense SNP in HSD3B7, Cheng et al., 2003; Song and Lee, 2013 PD Meta-analysis of PD miRNA GWAS data SNPs in a miRNA-binding site in the 3' UTR of HSD3B7 Ghanbari et al., 2016 ALS Peripheral blood cell eQTL of ALS and normal patients CYP27A1 eQTL Diekstra et al., 2012 AD Plasma metabolomic analysis of AD and normal patients Increased plasma GUDCA levels in patients with mild cognitive impairment or AD Mapstone et al., 2014 Biology of bile acids Two aspects of bile acid metabolism are relevant to their role in neurodegenerative disorders, bile acids that circulate systemically and that are synthesized by neurons. Circulating bile acids are largely synthesized from cholesterol in the liver (Prawitt et al., 2011). Ingestion of food causes bile acid secretion from the gallbladder through the common bile duct to the duodenum in order to facilitate the absorption of lipids and lipid-soluble vitamins via formation of micelles. Upon reaching the ileum, bile acids are transported by specific transport proteins to the portal circulation for recycling back to the liver. The process is highly efficient with over 95% of bile acids resorbed, the remaining 5% proceeding to the colon and excreted through the stool. Enterohepatic recycling of the bile acid pool occurs about 12 times per day, thus the net flux of bile acids through primarily the portal, but also the systemic, circulation is substantial. The two primary bile acids produced by the liver in humans are cholic acid (CA) and chenodeoxycholic acid (CDCA). These primary bile acids can undergo conjugation with glycine or taurine prior to secretion in the bile to form glycocholic acid (GCA), taurocholic acid (TCA), glycochenodeoxycholic acid (GCDCA), and taurochenodeoxycholic acid (TCDCA). In the intestine, they can undergo dehydroxylation by gut bacteria to produce deoxycholic acid (DCA) and lithocholic acid (LCA). Further chemical modifications can also occur resulting in other minor species such as ursodeoxycholic acid (UDCA) (Zhang et al., 1997). Bile acids also function as signaling molecules through interaction with several receptor systems (Figure 1). They serve as ligands for the nuclear transcription factor farnesoid X receptor (FXR), which forms a heterodimeric complex with retinoid X receptor α (RXRα) that binds to an inverted repeat sequence in gene promoters (Hoeke et al., 2014). They are also agonists for a cellular receptor, the G protein-coupled bile acid receptor 1 (GPBAR1 or TGR5), to mediate signaling via the generation of cyclic adenosine monophosphate (cAMP) by adenylate cyclase, which stimulates cAMP-dependent protein kinase A (PKA) and phosphorylation of the cAMP response element binding protein (CREB) transcription factor (Hodge and Nunez, 2016; Schonewille et al., 2016). Figure 1 Despite documented neuroprotective roles in models of neurodegenerative disorders, the primary signaling pathways (TGR5 and FXR) and the potential role of endogenous bile acids have not yet been studied. Alzheimer's disease Alzheimer's disease (AD) is characterized by dementia and memory loss that is associated with extracellular senile plaques of amyloid precursor protein derived amyloid-beta (Aβ) protein and intracellular neurofibrillary tangles consisting of the Tau protein (Scheltens et al., 2016). A primary in vitro model of AD is therefore treatment of cells with Aβ peptide that causes cytotoxicity to both primary cultures of neurons as well as neuronal cell lines. Treatment of primary cortical neuron cultures derived from Wistar rat embryos with tauroursodeoxycholic acid (TUDCA) prior to exposure to Aβ peptide significantly decreased nuclear fragmentation and cytochrome c release that was dependent upon activation of the PI3K pathway (Solá et al., 2003). The bile acid UDCA was found to regulate IκBα and NF-κB regulated genes in the mechanism of protection against Aβ toxicity in the BV-2 microglial cell line (Joo et al., 2004). Certain steroid hormones exhibit neuroprotective properties that are thought to be mediated in part through interaction with nuclear steroid receptors, including the glucocorticoid, and mineralocorticoid receptors (Garcia-Segura and Balthazart, 2009). Neurosteroids and bile acids are cholesterol derivatives that share some structural similarity so certain bile acids are natural ligands for these receptors. UDCA and TUDCA reduced Aβ induced apoptosis of primary rat cortical neurons that was found to be dependent upon the mineralocorticoid but not the glucocorticoid receptor (Sola et al., 2006). TUDCA appeared to interact with the ligand binding domain of the mineralocorticoid receptor to prevent its binding to heat shock protein 90 and subsequent trafficking for proteosomal processing allowing for translocation to the nucleus. Bile acids have also been studied in animal models of AD. In double transgenic mice (APP/PS1) that express human amyloid precursor protein carrying the KM670/671NL Swedish double mutation and the human presenilin 1 L166P mutation under the regulation of a neuron-specific promoter, treatment via dietary supplementation of standard laboratory chow with 0.4% (wt/wt) of TUDCA significantly reduced amyloid plaque number in the frontal cortex and hippocampus, decreased injury to neurons measured by determining loss of, or damage to, neuronal fibers surrounding plaques, and improved memory retention measured via contextual, though not auditory, fear conditioning (Nunes et al., 2012) as well as reduced hippocampal and prefrontal amyloid deposition (Lo et al., 2013). TUDCA has also been shown to help preserve the postsynaptic marker postsynaptic density-95 in the hippocampus of APP/PS1 mice (Ramalho et al., 2013). Repurposed RXR agonists or “rexinoids” have also shown some effectiveness in transgenic models of AD (Koster et al., 2016), suggesting a possible involvement of bile acids. In humans, a recent study of cognitively intact patients identified and validated a set of blood-based biomarkers that included glycoursodeoxycholic acid (GUDCA) that could predict the onset of either AD or amnestic mild cognitive impairment, considered an early precursor of AD, within 2–3 years with an accuracy of over 90% (Mapstone et al., 2014). This suggests a potential association of bile acids in the progression or preclinical neurodegenerative phase of AD. Parkinson's disease The effects of bile acids on chemical and genetic models of Parkinson's disease (PD), which is characterized by the selective loss of dopaminergic neurons in the substantia nigra region of the brain and a resulting tremor, have been reported. Sodium nitroprusside (SNP)-induced cytotoxicity of human dopaminergic SH-SY5Y cells has been used as a model of PD. UDCA was found to dose-dependently (50–200 μM) decrease SNP-related cell death. UDCA reduced reactive oxygen species (ROS), reactive nitrogen species (peroxynitrite and nitric oxide), and helped to maintain intracellular glutathione (GSH) levels. Apoptosis markers including nuclear fragmentation, caspase activation, and cytochrome c release were correspondingly reduced. Inhibiting phosphatidylinositiol-3-kinase (PI3K) and Akt/PKB blocked the favorable effects of UDCA on SNP-induced cytotoxic cell death (Chun and Low, 2012). Bile acids have also been implicated in PD through genetic association studies. In a meta-analysis of genome-wide association study (GWAS) data based on the genotypes of 2,525,705 SNPs in 4238 PD cases and 4239 non-PD controls, a total of 3 SNPs were found to be statistically associated with PD, including a non-synonymous missense variant in HSD3B7 (hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7) (Song and Lee, 2013). Recessive mutations in HSD3B7, which catalyzes the second step in the classical pathway of bile acid synthesis, are associated with loss of bile acid synthetic capability and progressive liver disease (Cheng et al., 2003). In a GWAS of 48,844 SNPs residing in miRNA-binding site variants, 32 SNPs were associated with PD that were located in the 3′ untranslated regions of 13 genes including HSD3B7 (Ghanbari et al., 2016), providing further genetic evidence for a role of bile acids in PD. Mitochondrial dysfunction has been associated with PD (Luo et al., 2015). To identify compounds that could restore mitochondrial function in skin fibroblasts obtained from patients with a PD parkin (PARK2) gene mutation, a 2000 compound library was screened for significant improvement in mitochondrial membrane potential (Mortiboys et al., 2013). Ursocholanic acid and the related compound dehydro(11,12)ursolic acid lactone were among the top 15 compounds that had dose response characteristics favorable for drug development and lacked many of the disadvantages of the other top hits. The structurally related bile acid UDCA was also found to rescue mitochondrial function to a similar extent, which was dependent upon activation of the glucocorticoid receptor and increased phosphorylation of Akt. UDCA was also found to restore mitochondrial function in fibroblasts obtained from a PD patient with a LRRK2-G2019S mutation. The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin is a widely used toxin model for PD, replicating most of the clinical and pathological features of PD in humans and animal models. TUDCA was found to play a role in ameliorating neurodegeneration in MPTP-induced degeneration of dopaminergic neurons in the nigrostriatal axis in C57BL/6 glutathione S-transferase pi (GSTP) null mice (Castro-Caldas et al., 2012). Treatment of mice with TUDCA prior to MPTP caused a 30% reduction in loss of dopaminergic neurons and reduced dopaminergic fiber loss. MPTP toxicity has also been associated with increased ROS production and activation of JNK-mediated apoptosis (Huang et al., 2016). TUDCA reduced levels of ROS and preserved levels of phosphorylated JNK (p-JNK) (Castro-Caldas et al., 2012). Amyotrophic lateral sclerosis The loss of motor neurons in Amyotrophic lateral sclerosis (ALS) has prompted therapeutic strategies aimed at preventing neuronal cell death and promoting regeneration (Carvalho et al., 2015). NSC-34 cells, created by fusion of cultured neuroblastoma cells and motor neurons from mouse spinal cord, can be treated with retinoic acid to induce neurite outgrowth and functional characteristics of motor neurons and are considered a highly stable and widely used murine motor neuron cell line model (Maier et al., 2013; Veyrat-Durebex et al., 2014). NSC-34 cells modified to carry the human form of SOD1 with the G93A mutation (hSOD1G93A) have thus been used as a model for ALS. GUDCA was reported to reduce cell death in the NSC-34 hSOD1G93A cell model and to block caspase-9 activation (Vaz et al., 2015). Bile acids also appear to have physiological roles in the central nervous system. CA, a bile acid present in the adult brain, was identified by LC/MS as a ligand of liver X receptor (LXR), activating LXR but not FXR in ventral midbrain dopaminergic neurons (Theofilopoulos et al., 2013). 6α-hydroxylated bile acids and the synthetic bile acid ligand GW3965 were also highly potent activators of LXR. Male LXR knockout mice develop an adult-onset motor neuron degeneration that is associated with impairment of motor coordination, axonal atrophy, astrogliosis, accumulation of lipid and loss of motor neurons in the spinal cord, findings similar to the neuropathology of ALS (Andersson et al., 2005). Additionally, FXR has been shown to contribute to normal motor function in mice (Huang et al., 2015). Several clinical trials of bile acids have been conducted in ALS patients in which evidence for safety and potential efficacy was observed (Parry et al., 2010; Min et al., 2012; Elia et al., 2016). In an ALS clinical trial with orally administered UDCA, the bile acid was found to be well tolerated and crossed into the cerebrospinal fluid in a dose-dependent manner (Parry et al., 2010). In a separate clinical trial to test the efficacy of UDCA for treating ALS patients, oral solubilized administration for 3 months was shown to be well tolerated and there was a slight decrease in the progression of ALS in the treatment group as compared to the placebo group (Min et al., 2012). However, due to the small size of the study and the high rate of patient dropout, the efficacy of the treatment was inconclusive. TUDCA administered orally twice per day for over 1 year resulted in a higher percentage of subjects achieving at least a 15% improvement in the ALS Functional Rating Scale Revised (ALSFRS-R) slope (Elia et al., 2016). Genetic data also implicates bile acid metabolism in ALS. Gene expression profiles obtained from the peripheral blood cells of sporadic ALS patients and normal controls were analyzed in the context of genome-wide SNP genotype data to identify expression quantitative trait loci (eQTLs). A cluster of transcript-SNP pairs with the highest level of statistical significance and meeting correction for multiple testing was associated with CYP27A1 expression in ALS (Diekstra et al., 2012). CYP27A1 is a key enzyme in the alternative bile acid synthesis pathway, and mutations in this enzyme can cause cerebrotendinous xanthomatosis as described below. Huntington's disease Huntington's disease (HD), an autosomal dominantly inherited neurodegenerative disease, is caused by an expansion mutation in CAG triplet repeat number in exon 1 of the huntingtin (HTT) gene (Ross et al., 2014). It is characterized by involuntary choreic movements, psychiatric and behavioral disturbances, and impaired cognitive function. Genetic and chemical animal and cellular models have been developed in which the effects of bile acids have been assessed. For example, 3-nitropropionic acid, an irreversible chemical inhibitor of mitochondrial succinate dehydrogenase, can be used to induce apoptosis of cells in culture and in neurons in the striatum region of the brain that causes changes similar to the morphology and neurochemical changes of HD. Incubation of rat neuronal RN33B cells with TUDCA was found to reduce 3-nitropropionic acid induced apoptosis by about 80% (Rodrigues et al., 2000). Other bile acids, including UDCA and GUDCA, were also associated with decreased apoptosis, preventing 3-nitropropionic acid induced release of mitochondrial cytochrome c, and associated morphological changes in both isolated mitochondria and in intact cells. In rats treated with TUDCA, a similar level of reduction in apoptosis and in the volume of lesions associated with administration of 3-nitropropionic acid was observed that was correlated with preservation of sensorimotor function and performance in cognitive task assays (Keene et al., 2001). These results suggest that the mechanisms of bile acid protection may be similar both in vitro and in vivo. Genetic models of HD have also been studied, including the R6/2 mouse, which is transgenic for a 150 repeat trinucleotide CAG expansion in exon 1 of HTT and manifests severe neurodegeneration, neuronal intranuclear inclusions, and sensorimotor deficits that result in a severely shortened survival of less than 4 months of age (Mangiarini et al., 1996; Davies et al., 1997). TUDCA treatment was administered to the R6/2 transgenic mice subcutaneously at a dose of 500 mg/kg once every 3 days from weaning to 6 months of age, which was tolerated without skin reaction or other effects. The subcutaneously administered TUDCA was absorbed into the circulation, crossed the blood-brain barrier, and produced seven-fold increases in UDCA levels in the brain without evidence of adverse effects. TUDCA treatment resulted in significantly reduced striatal cell apoptosis, decreased levels of intracellular inclusions, and improved locomotor open field and sensorimotor Rota-Rod performances (Keene et al., 2002). Spinocerebellar ataxia type 1 Spinocerebellar ataxia type 1 (SCA1) is another dominantly inherited neurodegenerative disorder characterized chiefly by progressive ataxia (Meera et al., 2016). SCA1 is caused by expansion of an unstable CAG trinucleotide repeat that encodes a glutamine tract in the Ataxin-1 gene (ATXN1). The disorder is characterized primarily by degeneration of Purkinje neurons of the cerebellum. TUDCA treatment was used to determine whether the survival of Purkinje cells and the onset and progression of ataxia was altered in a transgenic mouse model of SCA1, in which 30 copies of the human ATXN1 cDNA containing a CAG trinucleotide repeat of 82 repeats was under the control of the Pcp-2 Purkinje-cell specific promoter l (Kaemmerer et al., 2001). Despite the successful administration of TUDCA using a similar subcutaneous injection protocol as described above for the R6/2 transgenic HD mouse, and documentation of increased levels in the brain, no effects on cell survival or on the neurological phenotype were noted. The disparate effects in two different genetic models of neurodegenerative disease, suggest that bile acids target specific pathways. Prion diseases Neurodegenerative disorders caused by prions include Creutzfeldt-Jakob disease and similar disorders in animals such as bovine spongiform encephalopathy in cows, chronic wasting disease in deer, and scrapie in sheep (Imran and Mahmood, 2011; Windl and Dawson, 2012). Prion protein (PrPC) is a normal cellular protein that when mutated becomes misfolded (PrPSc). PrPSc can then convert normally folded PrPC to the misfolded form. Accumulation of PrPSc causes loss of neurons, astrogliosis, and spongiform degeneration resulting in dementia, ataxia, and death. One approach to therapeutic development has been to block or interfere with the conversion of PrPC to PrPSc. TUDCA and UDCA were found to substantially reduce this conversion in cell-free aggregation assays as well as in both chronically and acutely infected mouse ScN2a neuroblastoma cells (Cortez et al., 2015). TUDCA and UDCA also reduced neuronal loss in a prion organotypic slice culture model of intracerebral infection that assesses prion replication occurring ex vivo through infection of brain slices with prion infected brain homogenate. UDCA treatment also reduced astrocytosis and prolonged survival in prion infected male C57BL/6 mice, although whether bile acids interacted with the PrPC to PrPSc conversion or mediated protective effects through some other mechanism is not known. Cerebrotendinous xanthomatosis Cerebrotendinous xanthomatosis (CTX) is a very rare autosomal recessive disorder caused by mutations in the CYP27A1 gene (Björkhem and Hansson, 2010; Bjorkhem, 2013). These mutations lead to deficiency of the sterol 27-hydroxylase inner mitochondrial membrane protein. Sterol 27-hydroxylase oxidizes cholesterol to 27-hydroxycholesterol in the alternative bile acid synthesis pathway that leads to the generation of CDCA. Sterol 27-hydroxylase deficiency leads to a reduction of CDCA and upregulation of cholesterol 7α-hydroxylase (CYP7A1), the rate-limiting enzyme in the classic bile acid synthesis pathway resulting in elevated levels of cholestanol and bile alcohols. CTX patients have a mean age of diagnosis of 35 years and manifest multiple neurologic symptoms including dementia, ataxia, peripheral neuropathy, epilepsy, myopathy, and psychiatric disorders, as well as a variety of non-neurological manifestations including premature atherosclerosis, tendon xanthomas, juvenile onset cataracts, osteoporosis, and mild pulmonary insufficiency. Long-term treatment with CDCA can result in amelioration of neurological symptoms and an improved prognosis. Retinal diseases Bear bile has been used in Chinese medicine for several millennia to treat visual disorders (Boatright et al., 2006). This has led to a number of studies investigating the primary constituent of bear bile, TUDCA, as a potential therapeutic agent for several ophthalmological diseases (Boatright et al., 2009). TUDCA has been investigated in retinitis pigmentosa, a heterogeneous group of disorders of retinal degeneration in which progressive peripheral and night vision loss occurs, with central vision impairment. Mutations in about 200 genes, including the gene encoding rhodopsin (RHO), have been identified that cause apoptosis of photoreceptor cells (Daiger et al., 2013). The RHO P23H mutation is the most common cause of retinitis pigmentosa in the United States that is thought to produce structurally altered folding with retention in the endoplasmic reticulum and resulting cytotoxicity. TUDCA administered intraperitoneally once a week from weaning until 4 months of age to homozygous P23H line-3 rats reduced photoreceptor loss across the retina and preserved synapses between photoreceptors and bipolar or horizontal cells (Fernandez-Sanchez et al., 2011). In the rd10 mouse model of retinitis pigmentosa, in which the mice carry a missense mutation in exon 7 of the Pde6b gene resulting in rod photoreceptor cell death within a month after birth, subcutaneous administration of TUDCA resulted in higher cone cell density in all 4 quadrants of the retina (Oveson et al., 2011). TUDCA also decreased apoptosis, preserved the normal retinal photoreceptor cellular architecture, and maintained amplitudes of dark-adapted electroretinogram a- and b-waves (Boatright et al., 2006), even at later stages of severe photoreceptor loss (Phillips et al., 2008). Mutations in the retinoid isomerase (RPE65) or lecithin-retinol acyltransferase (LRAT) genes underlie Leber congenital amaurosis (den Hollander et al., 2008). LRAT is involved in 11-cis retinal recycling in the retinal pigment epithelium through mediating the esterification of all-trans retinol to all-trans retinyl esters, which are the substrates for RPE65. Homozygous Lrat knockout mice that were subcutaneously administered TUDCA every 3 days from 1 to 4 weeks after birth had about a three-fold increase in cone density in the ventral and central retina and increased ER-associated protein degradation (Zhang et al., 2012; Fu and Zhang, 2014). Twice per week subcutaneous injections of TUDCA also preserved ERG b-waves and the outer nuclear layer of the retina in Bardet-Biedl syndrome type 1 mice (Bbs1M390R/M390R), another model for retinal degeneration (Drack et al., 2012). TUDCA ameliorated cell death and loss of photoreceptor function after exposure to high levels of light (10,000 lux) that can induce retinal degeneration in albino Balb/C mice (Boatright et al., 2006). TUDCA pre-treatment of ex vivo perfused whole mount feline retinas repeatedly exposed to light stimulation and dark adaptations over 5 h resulted in greater receptive field size, decreased irradiance threshold, and maintenance of the contrast threshold (Xia et al., 2015). Retinal dystrophy can be caused by defects in the phagocytosis by retinal pigment epithelium cells of the photoreceptor outer segments that are shed, a continuous and extremely active process involving thousands of shed membranous disks each day. TUDCA was found to increase phagocytic activity and inhibit hydrogen peroxide induced impairment of phagocytosis by both cultured ARPE-19 cells and primary human retinal pigment epithelium cells (Murase et al., 2015). The phosphorylation of MerTK was significantly increased by TUDCA in a concentration-dependent manner but did not affect expression of the ER stress marker glucose regulated protein-78 (GRP-78). Bile acids also had an effect in ameliorating cell death in a model of retinal detachment via intraperitoneal injection of TUDCA at 3 and 5 days post detachment, times when acute photoreceptor loss occurs in the outer nuclear layer of the retina (Mantopoulos et al., 2011). TUDCA treatment also blocked the production of protein carbonyls with decreased caspase activation but did not decrease endoplasmic reticulum (ER) stress. In a diabetic retinopathy model, TUDCA significantly decreased apoptosis measured by TUNEL assay of primary rat retinal neural cells exposed to 30 mM glucose concentration, which causes caspase-independent cell death (Gaspar et al., 2013). TUDCA also decreased the amount of apoptosis-inducing factor (AIF) released from the mitochondria and its subsequent accumulation in the nucleus. Production of protein carbonyls and ROS were also significantly decreased after TUDCA treatment. Over-stimulation of N-methyl-D-aspartate (NMDA) receptors, one of three ionotropic glutamate receptor subtypes that are expressed in inner retinal cells, by intravitreal injection of NMDA has frequently been used to model the cell death pathway that occurs in retinal diseases such as glaucoma (Danesh-Meyer, 2011). This model of excitotoxicity causes disruption of sodium-potassium balance, calcium overload, mitochondrial dysfunction, and oxidative stress (Gomez-Vicente et al., 2015). In mice, administration of TUDCA prior to the intravitreal injection of NMDA was found to increase survival of retinal ganglion cells. Acute stroke, spinal cord injury, and neuropathy A single intravenous (i.v.) dose of TUDCA administered to rats 60 min after occlusion of the middle cerebral artery markedly reduced infarct size and apoptosis and preserved mitochondrial integrity (Rodrigues et al., 2002). The single i.v. dose resulted in a significant increase in brain UDCA levels from near undetectable levels to 0.15 nmol/g. TUDCA was also found to have an anti-inflammatory effect in the context of the central nervous system. TUDCA reduced glial cell activation and microglial chemotaxis and reduced expression of the MCP-1 chemoattractant and vascular adhesion proteins such as VCAM-1 in microglial cells and astrocytes treated with either interferon gamma (IFN-γ) or lipopolysaccharide and IFN-γ (Yanguas-Casás et al., 2014). Injection of TUDCA into the carotid artery 1 h prior to or up to 6 h after collagenase injection into the striatum to induce hemorrhagic lesions decreased lesion volumes, peri-hematoma apoptosis, and caspase activity at 2 days by about 50%, as well as decreased NF-κB and increased AKT activation that was associated with neurobehavioral improvement (Rodrigues et al., 2003). TUDCA injected intraperitoneally 1 min after spinal cord crush injury decreased apoptosis and corresponding tissue injury (Colak et al., 2008). In a phase II open-label study of oral doxycycline and TUDCA taken three times/day for 1 year in patients with transthyretin amyloidosis (ATTR), progression of neuropathy was stabilized (Obici et al., 2012). Modulation of neurotransmitter activity The wake period of normal mice was found to be increased with administration of UDCA that also decreased slow wave sleep (Yanovsky et al., 2012). In contrast, administration of UDCA to histidine decarboxylase knockout mice, that are deficient in histamine that stimulates arousal, decreased wakefulness and altered cortical EEG and sleep-wake parameters. Using in vitro patch-clamp recordings from histaminergic neurons, UDCA was found to inhibit GABAergic currents and to serve as an antagonist for GABAA receptors expressed in HEK293 cells. In one of the few studies to analyze more than one or two bile acids, a structure-function relationship analysis was performed using cultured hypothalamic neurons (Schubring et al., 2012). Bile acids were found to modulate firing frequency and synchrony, and to block activity of GABAA and NMDA receptors. Antagonist activity for both the GABAA and NMDA receptors was strongest for CDCA followed by DCA, CA, and dehydrocholate. Involvement of bile acid binding to TGR5 was excluded as a potential mechanism in the neurotransmitter receptor blockade (Keitel et al., 2010). CA was found to serve as an inhibiter for N-type Ca2+ channel currents of neurons isolated from the caudal paravertebral sympathetic ganglia of adult bull frogs (Rana catesbeiana), although open and shut times, slope conductance, and single channel current amplitude, were not significantly affected (Lee et al., 2012). Overstimulation of glutamate receptors to induce excitotoxicity in neurons isolated from late stage fetal rat brains was largely suppressed by GUDCA. This bile acid appeared to suppress glutamate release in either normal or microglia-depleted hippocampal tissue slices (Silva et al., 2012). Pretreatment of primary cultures of fetal rat cortical neurons with TUDCA significantly reduced glutamate excitotoxicity associated cell death. TUDCA treatment resulted in phosphorylation and translocation of the pro-apoptotic Bad protein from the mitochondria to the cytosol. Inhibiting the PI3K signaling pathway blocked the anti-apoptotic effects of TUDCA (Castro et al., 2004). Potential as neurotrophic factors Neurotrophic factors are classified primarily as proteins that bind to receptors, e.g., tropomyosin related kinase receptors TrkA, TrkB, and TrkC and p75 neurotrophin receptor (p75NTR) that can modulate Trk activation, to activate signaling pathways that promote neuronal growth and survival (Rodrigues et al., 2014). Several molecules have been identified as neurotrophic factors, including brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), and glial cell-line-derived neurotrophic factor (GDNF) that can stimulate the growth and differentiation of neuronal cells, as well as prevent cell death. Despite the therapeutic promise of such neurotrophic factors for treating neurodegenerative disorders (Tovar-Y-Romo et al., 2014), their limited bioavailability presents a major roadblock. Mimetics with more favorable bioavailability profiles have therefore been pursued (Tiwari and Chaturvedi, 2014), as well as investigation of proneurogenic peptides and small molecules that exhibit neuroprotective properties (Airavaara et al., 2012), including retinoic acid (Malik et al., 2000; Riancho et al., 2016). Retinoic acid shares a common role in regulating lipid homeostasis with bile acids, whose cognate receptor FXR can form heterodimers with RXRα. Thus, retinoic acid may activate the FXR signaling pathway and vice versa (Yang et al., 2014). Whether bile acids mediate effects in the nervous system through a similar mechanism is not known (Figure 1). Conclusions and outlook Neuroprotective effects of several bile acids are well documented in a wide range of neurodegenerative diseases, including AD, PD, ALS, HD, and retinal degeneration, in cellular and animal models and in human clinical trials. Due to the historical precedent set by the use of bear bile in ancient Chinese medicine, the majority of the studies have focused on UDCA and its derivatives. However, bile acids are a relatively large group of structurally related molecules, thus little is known about the potential efficacy of other bile acid species or the roles of circulating vs. endogenous bile acids synthesized within the central nervous system. In addition, most of the mechanistic studies have been centered on apoptosis and related pathways (Figure 2). However, essentially no data is available on the primary signaling pathways through which bile acids act, the cellular receptor TGR5 and the nuclear receptors FXR and RXRα, despite the well-known function of retinoic acid as a potent neurotrophic molecule. Determining the precise molecular mechanism(s) of neuroprotection by bile acids in neurodegenerative disorders will be important to realize their future therapeutic potential. Figure 2 Molecular pathways implicated in the neuroprotective effects of bile acids in neurodegenerative disease models. Despite the relatively large structurally related group of bile acids, relatively few have been studied in neurodegenerative disorders. A major focus has been on apoptotic pathways and the PI3 kinase and AKT signaling pathway. Surprisingly, the primary signaling pathways through which bile acids act, TGR5, FXR, and FXR/RXR have received essentially no attention (designated by “?”), despite that retinoic acid is known to be a potent neurotrophic molecule. Author contributions GG and HA designed, wrote, revised, and edited the manuscript. Both authors approved the submitted version of the manuscript. Funding This work was funded by the Lewis Katz School of Medicine at Temple University Department of Medical Genetics and Molecular Biochemistry and the Joseph & Rebecca Goodfriend Endowed Chair in Genetics. Conflict of interest statement The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
sec	Background Bile acids are a structurally related group of molecules derived from cholesterol that are widely known for their role as chemical detergents involved in the intestinal absorption and transport of fats and lipid-soluble nutrients (Schonewille et al., 2016). However, bile acids also appear to play as yet poorly defined physiological roles in the central nervous system (Lieu et al., 2014). Surprisingly little work has been done on the physiological roles of bile acids in neurons or the central nervous system (Zhang et al., 1997) despite a wide array of data in model systems and despite the significant therapeutic advantages of bile acids. Bile acids are readily bioavailable via oral, subcutaneous, or intravenous administration, can cross the blood-brain barrier, are relatively nontoxic, and have been approved by the U.S. Food and Drug Administration for human therapeutic use. We review evidence supporting a potentially therapeutic role for bile acids in a number of diverse neurodegenerative conditions. A summary of the studies described below is presented in Tables 1, 2. Table 1 Model system and human data implicating bile acids in neurodegenerative disorders. Disease/Phenotype Model Bile acid Mode of administration Dose or concentration Effects References Spinocerebellar ataxia type 1 (SCA1) Transgenic mouse with human ATXN1 with 82 CAG trinucleotide repeats under control of a Purkinje-cell promoter TUDCA Subcutaneous injection 500 mg/kg TUDCA crossed the blood-brain barrier but had no effect on cell survival Kaemmerer et al., 2001 Huntington's disease (HD) 3-nitropropionic acid-treated rat neuronal RN33B cells TUDCA Media 100 μM Decreased apoptosis by preventing mitochondrial depolarization and outer membrane disruption Rodrigues et al., 2000 GUDCA 500 μM UDCA 500 μM HD 3-nitropropionic acid-treated rats TUDCA Intraperitoneal injection 50 mg/kg Decreased apoptosis Keene et al., 2001 Reduced lesion volume Preserved sensorimotor and cognitive function HD R6/2 transgenic mouse with 150 CAG trinucleotide repeats in exon 1 of the huntingtin gene TUDCA Subcutaneous injection 500 mg/kg Reduced striatal cell apoptosis Keene et al., 2002 Decreased levels of intracellular inclusions Improved locomotor and sensorimotor function Parkinson's disease (PD) Sodium nitroprusside-treated human dopaminergic SH-SY5Y cells UDCA Media 50–200 μM Dose dependent inhibition of apoptosis via the PI3K- Chun and Low, 2012 Akt/PKB pathways Reduced ROS and reactive nitrogen species Maintained intracellular GSH levels PD Skin fibroblasts from PD patients UDCA Media 10–100 nM Restored mitochondrial function dependent upon glucocorticoid receptor activation and Akt phosphorylation Mortiboys et al., 2013 PD MPTP-induced mouse model TUDCA Intraperitoneal injection 50 mg/kg Reduction in loss of dopaminergic neurons by preserving levels of phosphorylated JNK, reducing ROS levels, and activating the Akt pathway Castro-Caldas et al., 2012 Alzheimer's disease (AD) Aβ-treated primary rat cortical neurons TUDCA Media 100 μM Decreased nuclear fragmentation and cytochrome c release through the PI3K pathway Solá et al., 2003 AD Aβ-treated mouse BV-2 microglial cells UDCA Media 250 μM Anti-inflammatory effect by inhibiting NF-κB activation Joo et al., 2004 AD Aβ-treated primary rat cortical neurons UDCA TUDCA Media 100 μM Decreased apoptosis dependent on interaction with the mineralocorticoid receptor Sola et al., 2006 AD Double transgenic APP/PS1 mice TUDCA Diet 0.4% wt/wt Reduced amyloid plaque number Nunes et al., 2012; Ramalho et al., 2013 Decreased injury to neurons Improved memory retention Decreased the loss of a postsynaptic marker in the hippocampus Amyotrophic lateral sclerosis (ALS) Mouse NSC-34 cells with the human SOD1G93A mutation GUDCA Media 50 μM Decreased cell death by blocking caspase-9 activation Vaz et al., 2015 ALS Primary mouse ventral midbrain cultures CA Media 10 μM Increased neuronal survival and promoted neurogenesis via LXR Theofilopoulos et al., 2013 ALS Clinical trial with ALS patients UDCA Oral Up to 50 mg/kg UDCA is well tolerated and well absorbed by oral administration Parry et al., 2010 UDCA crosses the blood-brain barrier in a dose-dependent manner ALS Clinical trial with ALS patients UDCA Oral 3.5 g/140 mL/day Slight decrease in progression of ALS but results were inconclusive Min et al., 2012 ALS Clinical trial with ALS patients TUDCA Oral 1 g, twice daily TUDCA is well tolerated Elia et al., 2016 Treatment resulted in improved function and slowed disease progression Prion disease Prion infected male mice UDCA Diet 0.01% wt/wt Reduced astrogliosis Cortez et al., 2015 Prolonged survival Cerebrotendinous xanthomatosis (CTX) Human patients CDCA Oral 15 mg/kg/day Amelioration of neurological symptoms Bjorkhem, 2013 Improved prognosis Retinitis pigmentosa (RP) Homozygous P23H rhodopsin transgenic rats TUDCA Intraperitoneal injection 500 mg/kg Reduced photoreceptor loss Fernandez-Sanchez et al., 2011 Preserved structure, function, and synaptic contacts of rods and cones RP Transgenic rd10 mouse model TUDCA Subcutaneous injection 500 mg/kg Higher cone cell density from decreased apoptosis Preserved structure and function of photoreceptor cells Boatright et al., 2006; Phillips et al., 2008; Oveson et al., 2011 Light-induced retinal degeneration Light-induced retinal damage (LIRD) mouse model TUDCA Subcutaneous injection 500 mg/kg Higher cone cell density from decreased apoptosis Preserved structure and function of photoreceptor cells Boatright et al., 2006; Phillips et al., 2008; Oveson et al., 2011 Leber congenital amaurosis Homozygous LRAT knockout mice TUDCA Subcutaneous injection 500 mg/kg Slowed cone degeneration in the ventral and central retina by preventing apoptosis and increasing ER-associated protein degradation Zhang et al., 2012; Fu and Zhang, 2014 In vitro retinal degeneration Whole mount cat retinas TUDCA Media 0.5 μM Greater receptive field size Xia et al., 2015 Decreased irradiance threshold Maintenance of the contrast threshold Retinal dystrophy Primary human retinal epithelium cells TUDCA Media 100 μM Protective against H2O2-induced impairment of phagocytosis Murase et al., 2015 Retinal detachment Subretinal injection of hyaluronic acid in rats TUDCA Intraperitoneal injection 500 mg/kg Reduced apoptosis in the outer nuclear layer of the retina Mantopoulos et al., 2011 Decreased caspase activation and protein carbonyl production Diabetic retinopathy Primary rat retinal neuron cells exposed to elevated glucose TUDCA Media 100 μM Decreased apoptosis Gaspar et al., 2013 Decreased mito-nuclear translocation of apoptosis-inducing factor (AIF) Decreased ROS and protein carbonyl production Retinal ganglion cell degeneration Intravitreal injection of NMDA in rats TUDCA Intraperitoneal injection 500 mg/kg Increased survival of retinal ganglion cells Gomez-Vicente et al., 2015 Ischemic stroke Middle cerebral artery occlusion in rats TUDCA Intravenous injection 400 mg/kg Reduction in infarct size Rodrigues et al., 2002 Reduced apoptosis Preserved mitochondrial integrity Hemorrhagic stroke Collagenase TUDCA Intra-arterial injection 200 mg/kg Decreased lesion volumes, peri-hematoma apoptosis, caspase activity, NF-κB activiation; increased AKT activation, neurobehavioral improvement Rodrigues et al., 2003 Acute neuroinflammation Intracerebro-ventricular injection with LPS in mice TUDCA Intraperitoneal injection 500 mg/kg Reduced glial cell activation Yanguas-Casás et al., 2014 Acute neuroinflammation Primary cultures of microglial cells and astrocytes from rats treated with LPS and/or IFN-γ TUDCA Media 200 μM Reduced microglial chemotaxis and expression of MCP-1 and VCAM-1 Yanguas-Casás et al., 2014 Sleep-wake pattern Wild type and histamine deficient mice UDCA Diet 32 mg/kg Promotes wakefulness through disinhibition of the histaminergic system via GABAA receptors Yanovsky et al., 2012 Hypothalamic network activity Primary cultures of mouse posterior hypothalamus CA Media Up to 8 mM Reduced firing, synchronized network activity, and blocked GABAA and NMDA receptor activity Schubring et al., 2012 GCA TCA DCA TDCA CDCA GCDCA TCDCA DHCA Neurotransmitter release Sympathetic ganglion neurons isolated from of adult bull frogs CA Media 1 μM Inhibits N-type calcium channel currents Lee et al., 2012 Hyperbilirubinemia Unconjugated bilirubin-treated organotypic-cultured hippocampal slices from rats GUDCA Media 50 mM Decreased cell death, NOS, glutamate release Silva et al., 2012 Glutamate-induced neurotoxicity Glutamate-treated primary rat cortical neurons TUDCA Media 100 μM Decreased apoptosis by activating a PI3K-dependent Bad signaling pathway Castro et al., 2004 Table 2 Genomic and metabolomics data implicating bile acids in neurodegenerative disorders. Disease Approach Genetic association References PD Meta-analysis of GWAS data from PD and normal patients HSD3B7 missense SNP in HSD3B7, Cheng et al., 2003; Song and Lee, 2013 PD Meta-analysis of PD miRNA GWAS data SNPs in a miRNA-binding site in the 3' UTR of HSD3B7 Ghanbari et al., 2016 ALS Peripheral blood cell eQTL of ALS and normal patients CYP27A1 eQTL Diekstra et al., 2012 AD Plasma metabolomic analysis of AD and normal patients Increased plasma GUDCA levels in patients with mild cognitive impairment or AD Mapstone et al., 2014
title	Background
p	Bile acids are a structurally related group of molecules derived from cholesterol that are widely known for their role as chemical detergents involved in the intestinal absorption and transport of fats and lipid-soluble nutrients (Schonewille et al., 2016). However, bile acids also appear to play as yet poorly defined physiological roles in the central nervous system (Lieu et al., 2014). Surprisingly little work has been done on the physiological roles of bile acids in neurons or the central nervous system (Zhang et al., 1997) despite a wide array of data in model systems and despite the significant therapeutic advantages of bile acids. Bile acids are readily bioavailable via oral, subcutaneous, or intravenous administration, can cross the blood-brain barrier, are relatively nontoxic, and have been approved by the U.S. Food and Drug Administration for human therapeutic use. We review evidence supporting a potentially therapeutic role for bile acids in a number of diverse neurodegenerative conditions. A summary of the studies described below is presented in Tables 1, 2.
table-wrap	Table 1 Model system and human data implicating bile acids in neurodegenerative disorders. Disease/Phenotype Model Bile acid Mode of administration Dose or concentration Effects References Spinocerebellar ataxia type 1 (SCA1) Transgenic mouse with human ATXN1 with 82 CAG trinucleotide repeats under control of a Purkinje-cell promoter TUDCA Subcutaneous injection 500 mg/kg TUDCA crossed the blood-brain barrier but had no effect on cell survival Kaemmerer et al., 2001 Huntington's disease (HD) 3-nitropropionic acid-treated rat neuronal RN33B cells TUDCA Media 100 μM Decreased apoptosis by preventing mitochondrial depolarization and outer membrane disruption Rodrigues et al., 2000 GUDCA 500 μM UDCA 500 μM HD 3-nitropropionic acid-treated rats TUDCA Intraperitoneal injection 50 mg/kg Decreased apoptosis Keene et al., 2001 Reduced lesion volume Preserved sensorimotor and cognitive function HD R6/2 transgenic mouse with 150 CAG trinucleotide repeats in exon 1 of the huntingtin gene TUDCA Subcutaneous injection 500 mg/kg Reduced striatal cell apoptosis Keene et al., 2002 Decreased levels of intracellular inclusions Improved locomotor and sensorimotor function Parkinson's disease (PD) Sodium nitroprusside-treated human dopaminergic SH-SY5Y cells UDCA Media 50–200 μM Dose dependent inhibition of apoptosis via the PI3K- Chun and Low, 2012 Akt/PKB pathways Reduced ROS and reactive nitrogen species Maintained intracellular GSH levels PD Skin fibroblasts from PD patients UDCA Media 10–100 nM Restored mitochondrial function dependent upon glucocorticoid receptor activation and Akt phosphorylation Mortiboys et al., 2013 PD MPTP-induced mouse model TUDCA Intraperitoneal injection 50 mg/kg Reduction in loss of dopaminergic neurons by preserving levels of phosphorylated JNK, reducing ROS levels, and activating the Akt pathway Castro-Caldas et al., 2012 Alzheimer's disease (AD) Aβ-treated primary rat cortical neurons TUDCA Media 100 μM Decreased nuclear fragmentation and cytochrome c release through the PI3K pathway Solá et al., 2003 AD Aβ-treated mouse BV-2 microglial cells UDCA Media 250 μM Anti-inflammatory effect by inhibiting NF-κB activation Joo et al., 2004 AD Aβ-treated primary rat cortical neurons UDCA TUDCA Media 100 μM Decreased apoptosis dependent on interaction with the mineralocorticoid receptor Sola et al., 2006 AD Double transgenic APP/PS1 mice TUDCA Diet 0.4% wt/wt Reduced amyloid plaque number Nunes et al., 2012; Ramalho et al., 2013 Decreased injury to neurons Improved memory retention Decreased the loss of a postsynaptic marker in the hippocampus Amyotrophic lateral sclerosis (ALS) Mouse NSC-34 cells with the human SOD1G93A mutation GUDCA Media 50 μM Decreased cell death by blocking caspase-9 activation Vaz et al., 2015 ALS Primary mouse ventral midbrain cultures CA Media 10 μM Increased neuronal survival and promoted neurogenesis via LXR Theofilopoulos et al., 2013 ALS Clinical trial with ALS patients UDCA Oral Up to 50 mg/kg UDCA is well tolerated and well absorbed by oral administration Parry et al., 2010 UDCA crosses the blood-brain barrier in a dose-dependent manner ALS Clinical trial with ALS patients UDCA Oral 3.5 g/140 mL/day Slight decrease in progression of ALS but results were inconclusive Min et al., 2012 ALS Clinical trial with ALS patients TUDCA Oral 1 g, twice daily TUDCA is well tolerated Elia et al., 2016 Treatment resulted in improved function and slowed disease progression Prion disease Prion infected male mice UDCA Diet 0.01% wt/wt Reduced astrogliosis Cortez et al., 2015 Prolonged survival Cerebrotendinous xanthomatosis (CTX) Human patients CDCA Oral 15 mg/kg/day Amelioration of neurological symptoms Bjorkhem, 2013 Improved prognosis Retinitis pigmentosa (RP) Homozygous P23H rhodopsin transgenic rats TUDCA Intraperitoneal injection 500 mg/kg Reduced photoreceptor loss Fernandez-Sanchez et al., 2011 Preserved structure, function, and synaptic contacts of rods and cones RP Transgenic rd10 mouse model TUDCA Subcutaneous injection 500 mg/kg Higher cone cell density from decreased apoptosis Preserved structure and function of photoreceptor cells Boatright et al., 2006; Phillips et al., 2008; Oveson et al., 2011 Light-induced retinal degeneration Light-induced retinal damage (LIRD) mouse model TUDCA Subcutaneous injection 500 mg/kg Higher cone cell density from decreased apoptosis Preserved structure and function of photoreceptor cells Boatright et al., 2006; Phillips et al., 2008; Oveson et al., 2011 Leber congenital amaurosis Homozygous LRAT knockout mice TUDCA Subcutaneous injection 500 mg/kg Slowed cone degeneration in the ventral and central retina by preventing apoptosis and increasing ER-associated protein degradation Zhang et al., 2012; Fu and Zhang, 2014 In vitro retinal degeneration Whole mount cat retinas TUDCA Media 0.5 μM Greater receptive field size Xia et al., 2015 Decreased irradiance threshold Maintenance of the contrast threshold Retinal dystrophy Primary human retinal epithelium cells TUDCA Media 100 μM Protective against H2O2-induced impairment of phagocytosis Murase et al., 2015 Retinal detachment Subretinal injection of hyaluronic acid in rats TUDCA Intraperitoneal injection 500 mg/kg Reduced apoptosis in the outer nuclear layer of the retina Mantopoulos et al., 2011 Decreased caspase activation and protein carbonyl production Diabetic retinopathy Primary rat retinal neuron cells exposed to elevated glucose TUDCA Media 100 μM Decreased apoptosis Gaspar et al., 2013 Decreased mito-nuclear translocation of apoptosis-inducing factor (AIF) Decreased ROS and protein carbonyl production Retinal ganglion cell degeneration Intravitreal injection of NMDA in rats TUDCA Intraperitoneal injection 500 mg/kg Increased survival of retinal ganglion cells Gomez-Vicente et al., 2015 Ischemic stroke Middle cerebral artery occlusion in rats TUDCA Intravenous injection 400 mg/kg Reduction in infarct size Rodrigues et al., 2002 Reduced apoptosis Preserved mitochondrial integrity Hemorrhagic stroke Collagenase TUDCA Intra-arterial injection 200 mg/kg Decreased lesion volumes, peri-hematoma apoptosis, caspase activity, NF-κB activiation; increased AKT activation, neurobehavioral improvement Rodrigues et al., 2003 Acute neuroinflammation Intracerebro-ventricular injection with LPS in mice TUDCA Intraperitoneal injection 500 mg/kg Reduced glial cell activation Yanguas-Casás et al., 2014 Acute neuroinflammation Primary cultures of microglial cells and astrocytes from rats treated with LPS and/or IFN-γ TUDCA Media 200 μM Reduced microglial chemotaxis and expression of MCP-1 and VCAM-1 Yanguas-Casás et al., 2014 Sleep-wake pattern Wild type and histamine deficient mice UDCA Diet 32 mg/kg Promotes wakefulness through disinhibition of the histaminergic system via GABAA receptors Yanovsky et al., 2012 Hypothalamic network activity Primary cultures of mouse posterior hypothalamus CA Media Up to 8 mM Reduced firing, synchronized network activity, and blocked GABAA and NMDA receptor activity Schubring et al., 2012 GCA TCA DCA TDCA CDCA GCDCA TCDCA DHCA Neurotransmitter release Sympathetic ganglion neurons isolated from of adult bull frogs CA Media 1 μM Inhibits N-type calcium channel currents Lee et al., 2012 Hyperbilirubinemia Unconjugated bilirubin-treated organotypic-cultured hippocampal slices from rats GUDCA Media 50 mM Decreased cell death, NOS, glutamate release Silva et al., 2012 Glutamate-induced neurotoxicity Glutamate-treated primary rat cortical neurons TUDCA Media 100 μM Decreased apoptosis by activating a PI3K-dependent Bad signaling pathway Castro et al., 2004
label	Table 1
caption	Model system and human data implicating bile acids in neurodegenerative disorders.
p	Model system and human data implicating bile acids in neurodegenerative disorders.
table	Disease/Phenotype Model Bile acid Mode of administration Dose or concentration Effects References Spinocerebellar ataxia type 1 (SCA1) Transgenic mouse with human ATXN1 with 82 CAG trinucleotide repeats under control of a Purkinje-cell promoter TUDCA Subcutaneous injection 500 mg/kg TUDCA crossed the blood-brain barrier but had no effect on cell survival Kaemmerer et al., 2001 Huntington's disease (HD) 3-nitropropionic acid-treated rat neuronal RN33B cells TUDCA Media 100 μM Decreased apoptosis by preventing mitochondrial depolarization and outer membrane disruption Rodrigues et al., 2000 GUDCA 500 μM UDCA 500 μM HD 3-nitropropionic acid-treated rats TUDCA Intraperitoneal injection 50 mg/kg Decreased apoptosis Keene et al., 2001 Reduced lesion volume Preserved sensorimotor and cognitive function HD R6/2 transgenic mouse with 150 CAG trinucleotide repeats in exon 1 of the huntingtin gene TUDCA Subcutaneous injection 500 mg/kg Reduced striatal cell apoptosis Keene et al., 2002 Decreased levels of intracellular inclusions Improved locomotor and sensorimotor function Parkinson's disease (PD) Sodium nitroprusside-treated human dopaminergic SH-SY5Y cells UDCA Media 50–200 μM Dose dependent inhibition of apoptosis via the PI3K- Chun and Low, 2012 Akt/PKB pathways Reduced ROS and reactive nitrogen species Maintained intracellular GSH levels PD Skin fibroblasts from PD patients UDCA Media 10–100 nM Restored mitochondrial function dependent upon glucocorticoid receptor activation and Akt phosphorylation Mortiboys et al., 2013 PD MPTP-induced mouse model TUDCA Intraperitoneal injection 50 mg/kg Reduction in loss of dopaminergic neurons by preserving levels of phosphorylated JNK, reducing ROS levels, and activating the Akt pathway Castro-Caldas et al., 2012 Alzheimer's disease (AD) Aβ-treated primary rat cortical neurons TUDCA Media 100 μM Decreased nuclear fragmentation and cytochrome c release through the PI3K pathway Solá et al., 2003 AD Aβ-treated mouse BV-2 microglial cells UDCA Media 250 μM Anti-inflammatory effect by inhibiting NF-κB activation Joo et al., 2004 AD Aβ-treated primary rat cortical neurons UDCA TUDCA Media 100 μM Decreased apoptosis dependent on interaction with the mineralocorticoid receptor Sola et al., 2006 AD Double transgenic APP/PS1 mice TUDCA Diet 0.4% wt/wt Reduced amyloid plaque number Nunes et al., 2012; Ramalho et al., 2013 Decreased injury to neurons Improved memory retention Decreased the loss of a postsynaptic marker in the hippocampus Amyotrophic lateral sclerosis (ALS) Mouse NSC-34 cells with the human SOD1G93A mutation GUDCA Media 50 μM Decreased cell death by blocking caspase-9 activation Vaz et al., 2015 ALS Primary mouse ventral midbrain cultures CA Media 10 μM Increased neuronal survival and promoted neurogenesis via LXR Theofilopoulos et al., 2013 ALS Clinical trial with ALS patients UDCA Oral Up to 50 mg/kg UDCA is well tolerated and well absorbed by oral administration Parry et al., 2010 UDCA crosses the blood-brain barrier in a dose-dependent manner ALS Clinical trial with ALS patients UDCA Oral 3.5 g/140 mL/day Slight decrease in progression of ALS but results were inconclusive Min et al., 2012 ALS Clinical trial with ALS patients TUDCA Oral 1 g, twice daily TUDCA is well tolerated Elia et al., 2016 Treatment resulted in improved function and slowed disease progression Prion disease Prion infected male mice UDCA Diet 0.01% wt/wt Reduced astrogliosis Cortez et al., 2015 Prolonged survival Cerebrotendinous xanthomatosis (CTX) Human patients CDCA Oral 15 mg/kg/day Amelioration of neurological symptoms Bjorkhem, 2013 Improved prognosis Retinitis pigmentosa (RP) Homozygous P23H rhodopsin transgenic rats TUDCA Intraperitoneal injection 500 mg/kg Reduced photoreceptor loss Fernandez-Sanchez et al., 2011 Preserved structure, function, and synaptic contacts of rods and cones RP Transgenic rd10 mouse model TUDCA Subcutaneous injection 500 mg/kg Higher cone cell density from decreased apoptosis Preserved structure and function of photoreceptor cells Boatright et al., 2006; Phillips et al., 2008; Oveson et al., 2011 Light-induced retinal degeneration Light-induced retinal damage (LIRD) mouse model TUDCA Subcutaneous injection 500 mg/kg Higher cone cell density from decreased apoptosis Preserved structure and function of photoreceptor cells Boatright et al., 2006; Phillips et al., 2008; Oveson et al., 2011 Leber congenital amaurosis Homozygous LRAT knockout mice TUDCA Subcutaneous injection 500 mg/kg Slowed cone degeneration in the ventral and central retina by preventing apoptosis and increasing ER-associated protein degradation Zhang et al., 2012; Fu and Zhang, 2014 In vitro retinal degeneration Whole mount cat retinas TUDCA Media 0.5 μM Greater receptive field size Xia et al., 2015 Decreased irradiance threshold Maintenance of the contrast threshold Retinal dystrophy Primary human retinal epithelium cells TUDCA Media 100 μM Protective against H2O2-induced impairment of phagocytosis Murase et al., 2015 Retinal detachment Subretinal injection of hyaluronic acid in rats TUDCA Intraperitoneal injection 500 mg/kg Reduced apoptosis in the outer nuclear layer of the retina Mantopoulos et al., 2011 Decreased caspase activation and protein carbonyl production Diabetic retinopathy Primary rat retinal neuron cells exposed to elevated glucose TUDCA Media 100 μM Decreased apoptosis Gaspar et al., 2013 Decreased mito-nuclear translocation of apoptosis-inducing factor (AIF) Decreased ROS and protein carbonyl production Retinal ganglion cell degeneration Intravitreal injection of NMDA in rats TUDCA Intraperitoneal injection 500 mg/kg Increased survival of retinal ganglion cells Gomez-Vicente et al., 2015 Ischemic stroke Middle cerebral artery occlusion in rats TUDCA Intravenous injection 400 mg/kg Reduction in infarct size Rodrigues et al., 2002 Reduced apoptosis Preserved mitochondrial integrity Hemorrhagic stroke Collagenase TUDCA Intra-arterial injection 200 mg/kg Decreased lesion volumes, peri-hematoma apoptosis, caspase activity, NF-κB activiation; increased AKT activation, neurobehavioral improvement Rodrigues et al., 2003 Acute neuroinflammation Intracerebro-ventricular injection with LPS in mice TUDCA Intraperitoneal injection 500 mg/kg Reduced glial cell activation Yanguas-Casás et al., 2014 Acute neuroinflammation Primary cultures of microglial cells and astrocytes from rats treated with LPS and/or IFN-γ TUDCA Media 200 μM Reduced microglial chemotaxis and expression of MCP-1 and VCAM-1 Yanguas-Casás et al., 2014 Sleep-wake pattern Wild type and histamine deficient mice UDCA Diet 32 mg/kg Promotes wakefulness through disinhibition of the histaminergic system via GABAA receptors Yanovsky et al., 2012 Hypothalamic network activity Primary cultures of mouse posterior hypothalamus CA Media Up to 8 mM Reduced firing, synchronized network activity, and blocked GABAA and NMDA receptor activity Schubring et al., 2012 GCA TCA DCA TDCA CDCA GCDCA TCDCA DHCA Neurotransmitter release Sympathetic ganglion neurons isolated from of adult bull frogs CA Media 1 μM Inhibits N-type calcium channel currents Lee et al., 2012 Hyperbilirubinemia Unconjugated bilirubin-treated organotypic-cultured hippocampal slices from rats GUDCA Media 50 mM Decreased cell death, NOS, glutamate release Silva et al., 2012 Glutamate-induced neurotoxicity Glutamate-treated primary rat cortical neurons TUDCA Media 100 μM Decreased apoptosis by activating a PI3K-dependent Bad signaling pathway Castro et al., 2004
tr	Disease/Phenotype Model Bile acid Mode of administration Dose or concentration Effects References
th	Disease/Phenotype
th	Model
th	Bile acid
th	Mode of administration
th	Dose or concentration
th	Effects
th	References
tr	Spinocerebellar ataxia type 1 (SCA1) Transgenic mouse with human ATXN1 with 82 CAG trinucleotide repeats under control of a Purkinje-cell promoter TUDCA Subcutaneous injection 500 mg/kg TUDCA crossed the blood-brain barrier but had no effect on cell survival Kaemmerer et al., 2001
td	Spinocerebellar ataxia type 1 (SCA1)
td	Transgenic mouse with human ATXN1 with 82 CAG trinucleotide repeats under control of a Purkinje-cell promoter
td	TUDCA
td	Subcutaneous injection
td	500 mg/kg
td	TUDCA crossed the blood-brain barrier but had no effect on cell survival
td	Kaemmerer et al., 2001
tr	Huntington's disease (HD) 3-nitropropionic acid-treated rat neuronal RN33B cells TUDCA Media 100 μM Decreased apoptosis by preventing mitochondrial depolarization and outer membrane disruption Rodrigues et al., 2000
td	Huntington's disease (HD)
td	3-nitropropionic acid-treated rat neuronal RN33B cells
td	TUDCA
td	Media
td	100 μM
td	Decreased apoptosis by preventing mitochondrial depolarization and outer membrane disruption
td	Rodrigues et al., 2000
tr	GUDCA 500 μM
td	GUDCA
td	500 μM
tr	UDCA 500 μM
td	UDCA
td	500 μM
tr	HD 3-nitropropionic acid-treated rats TUDCA Intraperitoneal injection 50 mg/kg Decreased apoptosis Keene et al., 2001
td	HD
td	3-nitropropionic acid-treated rats
td	TUDCA
td	Intraperitoneal injection
td	50 mg/kg
td	Decreased apoptosis
td	Keene et al., 2001
tr	Reduced lesion volume
td	Reduced lesion volume
tr	Preserved sensorimotor and cognitive function
td	Preserved sensorimotor and cognitive function
tr	HD R6/2 transgenic mouse with 150 CAG trinucleotide repeats in exon 1 of the huntingtin gene TUDCA Subcutaneous injection 500 mg/kg Reduced striatal cell apoptosis Keene et al., 2002
td	HD
td	R6/2 transgenic mouse with 150 CAG trinucleotide repeats in exon 1 of the huntingtin gene
td	TUDCA
td	Subcutaneous injection
td	500 mg/kg
td	Reduced striatal cell apoptosis
td	Keene et al., 2002
tr	Decreased levels of intracellular inclusions
td	Decreased levels of intracellular inclusions
tr	Improved locomotor and sensorimotor function
td	Improved locomotor and sensorimotor function
tr	Parkinson's disease (PD) Sodium nitroprusside-treated human dopaminergic SH-SY5Y cells UDCA Media 50–200 μM Dose dependent inhibition of apoptosis via the PI3K- Chun and Low, 2012
td	Parkinson's disease (PD)
td	Sodium nitroprusside-treated human dopaminergic SH-SY5Y cells
td	UDCA
td	Media
td	50–200 μM
td	Dose dependent inhibition of apoptosis via the PI3K-
td	Chun and Low, 2012
tr	Akt/PKB pathways
td	Akt/PKB pathways
tr	Reduced ROS and reactive nitrogen species
td	Reduced ROS and reactive nitrogen species
tr	Maintained intracellular GSH levels
td	Maintained intracellular GSH levels
tr	PD Skin fibroblasts from PD patients UDCA Media 10–100 nM Restored mitochondrial function dependent upon glucocorticoid receptor activation and Akt phosphorylation Mortiboys et al., 2013
td	PD
td	Skin fibroblasts from PD patients
td	UDCA
td	Media
td	10–100 nM
td	Restored mitochondrial function dependent upon glucocorticoid receptor activation and Akt phosphorylation
td	Mortiboys et al., 2013
tr	PD MPTP-induced mouse model TUDCA Intraperitoneal injection 50 mg/kg Reduction in loss of dopaminergic neurons by preserving levels of phosphorylated JNK, reducing ROS levels, and activating the Akt pathway Castro-Caldas et al., 2012
td	PD
td	MPTP-induced mouse model
td	TUDCA
td	Intraperitoneal injection
td	50 mg/kg
td	Reduction in loss of dopaminergic neurons by preserving levels of phosphorylated JNK, reducing ROS levels, and activating the Akt pathway
td	Castro-Caldas et al., 2012
tr	Alzheimer's disease (AD) Aβ-treated primary rat cortical neurons TUDCA Media 100 μM Decreased nuclear fragmentation and cytochrome c release through the PI3K pathway Solá et al., 2003
td	Alzheimer's disease (AD)
td	Aβ-treated primary rat cortical neurons
td	TUDCA
td	Media
td	100 μM
td	Decreased nuclear fragmentation and cytochrome c release through the PI3K pathway
td	Solá et al., 2003
tr	AD Aβ-treated mouse BV-2 microglial cells UDCA Media 250 μM Anti-inflammatory effect by inhibiting NF-κB activation Joo et al., 2004
td	AD
td	Aβ-treated mouse BV-2 microglial cells
td	UDCA
td	Media
td	250 μM
td	Anti-inflammatory effect by inhibiting NF-κB activation
td	Joo et al., 2004
tr	AD Aβ-treated primary rat cortical neurons UDCA TUDCA Media 100 μM Decreased apoptosis dependent on interaction with the mineralocorticoid receptor Sola et al., 2006
td	AD
td	Aβ-treated primary rat cortical neurons
td	UDCA TUDCA
td	Media
td	100 μM
td	Decreased apoptosis dependent on interaction with the mineralocorticoid receptor
td	Sola et al., 2006
tr	AD Double transgenic APP/PS1 mice TUDCA Diet 0.4% wt/wt Reduced amyloid plaque number Nunes et al., 2012; Ramalho et al., 2013
td	AD
td	Double transgenic APP/PS1 mice
td	TUDCA
td	Diet
td	0.4% wt/wt
td	Reduced amyloid plaque number
td	Nunes et al., 2012; Ramalho et al., 2013
tr	Decreased injury to neurons
td	Decreased injury to neurons
tr	Improved memory retention
td	Improved memory retention
tr	Decreased the loss of a postsynaptic marker in the hippocampus
td	Decreased the loss of a postsynaptic marker in the hippocampus
tr	Amyotrophic lateral sclerosis (ALS) Mouse NSC-34 cells with the human SOD1G93A mutation GUDCA Media 50 μM Decreased cell death by blocking caspase-9 activation Vaz et al., 2015
td	Amyotrophic lateral sclerosis (ALS)
td	Mouse NSC-34 cells with the human SOD1G93A mutation
td	GUDCA
td	Media
td	50 μM
td	Decreased cell death by blocking caspase-9 activation
td	Vaz et al., 2015
tr	ALS Primary mouse ventral midbrain cultures CA Media 10 μM Increased neuronal survival and promoted neurogenesis via LXR Theofilopoulos et al., 2013
td	ALS
td	Primary mouse ventral midbrain cultures
td	CA
td	Media
td	10 μM
td	Increased neuronal survival and promoted neurogenesis via LXR
td	Theofilopoulos et al., 2013
tr	ALS Clinical trial with ALS patients UDCA Oral Up to 50 mg/kg UDCA is well tolerated and well absorbed by oral administration Parry et al., 2010
td	ALS
td	Clinical trial with ALS patients
td	UDCA
td	Oral
td	Up to 50 mg/kg
td	UDCA is well tolerated and well absorbed by oral administration
td	Parry et al., 2010
tr	UDCA crosses the blood-brain barrier in a dose-dependent manner
td	UDCA crosses the blood-brain barrier in a dose-dependent manner
tr	ALS Clinical trial with ALS patients UDCA Oral 3.5 g/140 mL/day Slight decrease in progression of ALS but results were inconclusive Min et al., 2012
td	ALS
td	Clinical trial with ALS patients
td	UDCA
td	Oral
td	3.5 g/140 mL/day
td	Slight decrease in progression of ALS but results were inconclusive
td	Min et al., 2012
tr	ALS Clinical trial with ALS patients TUDCA Oral 1 g, twice daily TUDCA is well tolerated Elia et al., 2016
td	ALS
td	Clinical trial with ALS patients
td	TUDCA
td	Oral
td	1 g, twice daily
td	TUDCA is well tolerated
td	Elia et al., 2016
tr	Treatment resulted in improved function and slowed disease progression
td	Treatment resulted in improved function and slowed disease progression
tr	Prion disease Prion infected male mice UDCA Diet 0.01% wt/wt Reduced astrogliosis Cortez et al., 2015
td	Prion disease
td	Prion infected male mice
td	UDCA
td	Diet
td	0.01% wt/wt
td	Reduced astrogliosis
td	Cortez et al., 2015
tr	Prolonged survival
td	Prolonged survival
tr	Cerebrotendinous xanthomatosis (CTX) Human patients CDCA Oral 15 mg/kg/day Amelioration of neurological symptoms Bjorkhem, 2013
td	Cerebrotendinous xanthomatosis (CTX)
td	Human patients
td	CDCA
td	Oral
td	15 mg/kg/day
td	Amelioration of neurological symptoms
td	Bjorkhem, 2013
tr	Improved prognosis
td	Improved prognosis
tr	Retinitis pigmentosa (RP) Homozygous P23H rhodopsin transgenic rats TUDCA Intraperitoneal injection 500 mg/kg Reduced photoreceptor loss Fernandez-Sanchez et al., 2011
td	Retinitis pigmentosa (RP)
td	Homozygous P23H rhodopsin transgenic rats
td	TUDCA
td	Intraperitoneal injection
td	500 mg/kg
td	Reduced photoreceptor loss
td	Fernandez-Sanchez et al., 2011
tr	Preserved structure, function, and synaptic contacts of rods and cones
td	Preserved structure, function, and synaptic contacts of rods and cones
tr	RP Transgenic rd10 mouse model TUDCA Subcutaneous injection 500 mg/kg Higher cone cell density from decreased apoptosis Preserved structure and function of photoreceptor cells Boatright et al., 2006; Phillips et al., 2008; Oveson et al., 2011
td	RP
td	Transgenic rd10 mouse model
td	TUDCA
td	Subcutaneous injection
td	500 mg/kg
td	Higher cone cell density from decreased apoptosis Preserved structure and function of photoreceptor cells
td	Boatright et al., 2006; Phillips et al., 2008; Oveson et al., 2011
tr	Light-induced retinal degeneration Light-induced retinal damage (LIRD) mouse model TUDCA Subcutaneous injection 500 mg/kg Higher cone cell density from decreased apoptosis Preserved structure and function of photoreceptor cells Boatright et al., 2006; Phillips et al., 2008; Oveson et al., 2011
td	Light-induced retinal degeneration
td	Light-induced retinal damage (LIRD) mouse model
td	TUDCA
td	Subcutaneous injection
td	500 mg/kg
td	Higher cone cell density from decreased apoptosis Preserved structure and function of photoreceptor cells
td	Boatright et al., 2006; Phillips et al., 2008; Oveson et al., 2011
tr	Leber congenital amaurosis Homozygous LRAT knockout mice TUDCA Subcutaneous injection 500 mg/kg Slowed cone degeneration in the ventral and central retina by preventing apoptosis and increasing ER-associated protein degradation Zhang et al., 2012; Fu and Zhang, 2014
td	Leber congenital amaurosis
td	Homozygous LRAT knockout mice
td	TUDCA
td	Subcutaneous injection
td	500 mg/kg
td	Slowed cone degeneration in the ventral and central retina by preventing apoptosis and increasing ER-associated protein degradation
td	Zhang et al., 2012; Fu and Zhang, 2014
tr	In vitro retinal degeneration Whole mount cat retinas TUDCA Media 0.5 μM Greater receptive field size Xia et al., 2015
td	In vitro retinal degeneration
td	Whole mount cat retinas
td	TUDCA
td	Media
td	0.5 μM
td	Greater receptive field size
td	Xia et al., 2015
tr	Decreased irradiance threshold
td	Decreased irradiance threshold
tr	Maintenance of the contrast threshold
td	Maintenance of the contrast threshold
tr	Retinal dystrophy Primary human retinal epithelium cells TUDCA Media 100 μM Protective against H2O2-induced impairment of phagocytosis Murase et al., 2015
td	Retinal dystrophy
td	Primary human retinal epithelium cells
td	TUDCA
td	Media
td	100 μM
td	Protective against H2O2-induced impairment of phagocytosis
td	Murase et al., 2015
tr	Retinal detachment Subretinal injection of hyaluronic acid in rats TUDCA Intraperitoneal injection 500 mg/kg Reduced apoptosis in the outer nuclear layer of the retina Mantopoulos et al., 2011
td	Retinal detachment
td	Subretinal injection of hyaluronic acid in rats
td	TUDCA
td	Intraperitoneal injection
td	500 mg/kg
td	Reduced apoptosis in the outer nuclear layer of the retina
td	Mantopoulos et al., 2011
tr	Decreased caspase activation and protein carbonyl production
td	Decreased caspase activation and protein carbonyl production
tr	Diabetic retinopathy Primary rat retinal neuron cells exposed to elevated glucose TUDCA Media 100 μM Decreased apoptosis Gaspar et al., 2013
td	Diabetic retinopathy
td	Primary rat retinal neuron cells exposed to elevated glucose
td	TUDCA
td	Media
td	100 μM
td	Decreased apoptosis
td	Gaspar et al., 2013
tr	Decreased mito-nuclear translocation of apoptosis-inducing factor (AIF)
td	Decreased mito-nuclear translocation of apoptosis-inducing factor (AIF)
tr	Decreased ROS and protein carbonyl production
td	Decreased ROS and protein carbonyl production
tr	Retinal ganglion cell degeneration Intravitreal injection of NMDA in rats TUDCA Intraperitoneal injection 500 mg/kg Increased survival of retinal ganglion cells Gomez-Vicente et al., 2015
td	Retinal ganglion cell degeneration
td	Intravitreal injection of NMDA in rats
td	TUDCA
td	Intraperitoneal injection
td	500 mg/kg
td	Increased survival of retinal ganglion cells
td	Gomez-Vicente et al., 2015
tr	Ischemic stroke Middle cerebral artery occlusion in rats TUDCA Intravenous injection 400 mg/kg Reduction in infarct size Rodrigues et al., 2002
td	Ischemic stroke
td	Middle cerebral artery occlusion in rats
td	TUDCA
td	Intravenous injection
td	400 mg/kg
td	Reduction in infarct size
td	Rodrigues et al., 2002
tr	Reduced apoptosis
td	Reduced apoptosis
tr	Preserved mitochondrial integrity
td	Preserved mitochondrial integrity
tr	Hemorrhagic stroke Collagenase TUDCA Intra-arterial injection 200 mg/kg Decreased lesion volumes, peri-hematoma apoptosis, caspase activity, NF-κB activiation; increased AKT activation, neurobehavioral improvement Rodrigues et al., 2003
td	Hemorrhagic stroke
td	Collagenase
td	TUDCA
td	Intra-arterial injection
td	200 mg/kg
td	Decreased lesion volumes, peri-hematoma apoptosis, caspase activity, NF-κB activiation; increased AKT activation, neurobehavioral improvement
td	Rodrigues et al., 2003
tr	Acute neuroinflammation Intracerebro-ventricular injection with LPS in mice TUDCA Intraperitoneal injection 500 mg/kg Reduced glial cell activation Yanguas-Casás et al., 2014
td	Acute neuroinflammation
td	Intracerebro-ventricular injection with LPS in mice
td	TUDCA
td	Intraperitoneal injection
td	500 mg/kg
td	Reduced glial cell activation
td	Yanguas-Casás et al., 2014
tr	Acute neuroinflammation Primary cultures of microglial cells and astrocytes from rats treated with LPS and/or IFN-γ TUDCA Media 200 μM Reduced microglial chemotaxis and expression of MCP-1 and VCAM-1 Yanguas-Casás et al., 2014
td	Acute neuroinflammation
td	Primary cultures of microglial cells and astrocytes from rats treated with LPS and/or IFN-γ
td	TUDCA
td	Media
td	200 μM
td	Reduced microglial chemotaxis and expression of MCP-1 and VCAM-1
td	Yanguas-Casás et al., 2014
tr	Sleep-wake pattern Wild type and histamine deficient mice UDCA Diet 32 mg/kg Promotes wakefulness through disinhibition of the histaminergic system via GABAA receptors Yanovsky et al., 2012
td	Sleep-wake pattern
td	Wild type and histamine deficient mice
td	UDCA
td	Diet
td	32 mg/kg
td	Promotes wakefulness through disinhibition of the histaminergic system via GABAA receptors
td	Yanovsky et al., 2012
tr	Hypothalamic network activity Primary cultures of mouse posterior hypothalamus CA Media Up to 8 mM Reduced firing, synchronized network activity, and blocked GABAA and NMDA receptor activity Schubring et al., 2012
td	Hypothalamic network activity
td	Primary cultures of mouse posterior hypothalamus
td	CA
td	Media
td	Up to 8 mM
td	Reduced firing, synchronized network activity, and blocked GABAA and NMDA receptor activity
td	Schubring et al., 2012
tr	GCA
td	GCA
tr	TCA
td	TCA
tr	DCA
td	DCA
tr	TDCA
td	TDCA
tr	CDCA
td	CDCA
tr	GCDCA
td	GCDCA
tr	TCDCA
td	TCDCA
tr	DHCA
td	DHCA
tr	Neurotransmitter release Sympathetic ganglion neurons isolated from of adult bull frogs CA Media 1 μM Inhibits N-type calcium channel currents Lee et al., 2012
td	Neurotransmitter release
td	Sympathetic ganglion neurons isolated from of adult bull frogs
td	CA
td	Media
td	1 μM
td	Inhibits N-type calcium channel currents
td	Lee et al., 2012
tr	Hyperbilirubinemia Unconjugated bilirubin-treated organotypic-cultured hippocampal slices from rats GUDCA Media 50 mM Decreased cell death, NOS, glutamate release Silva et al., 2012
td	Hyperbilirubinemia
td	Unconjugated bilirubin-treated organotypic-cultured hippocampal slices from rats
td	GUDCA
td	Media
td	50 mM
td	Decreased cell death, NOS, glutamate release
td	Silva et al., 2012
tr	Glutamate-induced neurotoxicity Glutamate-treated primary rat cortical neurons TUDCA Media 100 μM Decreased apoptosis by activating a PI3K-dependent Bad signaling pathway Castro et al., 2004
td	Glutamate-induced neurotoxicity
td	Glutamate-treated primary rat cortical neurons
td	TUDCA
td	Media
td	100 μM
td	Decreased apoptosis by activating a PI3K-dependent Bad signaling pathway
td	Castro et al., 2004
table-wrap	Table 2 Genomic and metabolomics data implicating bile acids in neurodegenerative disorders. Disease Approach Genetic association References PD Meta-analysis of GWAS data from PD and normal patients HSD3B7 missense SNP in HSD3B7, Cheng et al., 2003; Song and Lee, 2013 PD Meta-analysis of PD miRNA GWAS data SNPs in a miRNA-binding site in the 3' UTR of HSD3B7 Ghanbari et al., 2016 ALS Peripheral blood cell eQTL of ALS and normal patients CYP27A1 eQTL Diekstra et al., 2012 AD Plasma metabolomic analysis of AD and normal patients Increased plasma GUDCA levels in patients with mild cognitive impairment or AD Mapstone et al., 2014
label	Table 2
caption	Genomic and metabolomics data implicating bile acids in neurodegenerative disorders.
p	Genomic and metabolomics data implicating bile acids in neurodegenerative disorders.
table	Disease Approach Genetic association References PD Meta-analysis of GWAS data from PD and normal patients HSD3B7 missense SNP in HSD3B7, Cheng et al., 2003; Song and Lee, 2013 PD Meta-analysis of PD miRNA GWAS data SNPs in a miRNA-binding site in the 3' UTR of HSD3B7 Ghanbari et al., 2016 ALS Peripheral blood cell eQTL of ALS and normal patients CYP27A1 eQTL Diekstra et al., 2012 AD Plasma metabolomic analysis of AD and normal patients Increased plasma GUDCA levels in patients with mild cognitive impairment or AD Mapstone et al., 2014
tr	Disease Approach Genetic association References
th	Disease
th	Approach
th	Genetic association
th	References
tr	PD Meta-analysis of GWAS data from PD and normal patients HSD3B7 missense SNP in HSD3B7, Cheng et al., 2003; Song and Lee, 2013
td	PD
td	Meta-analysis of GWAS data from PD and normal patients
td	HSD3B7 missense SNP in HSD3B7,
td	Cheng et al., 2003; Song and Lee, 2013
tr	PD Meta-analysis of PD miRNA GWAS data SNPs in a miRNA-binding site in the 3' UTR of HSD3B7 Ghanbari et al., 2016
td	PD
td	Meta-analysis of PD miRNA GWAS data
td	SNPs in a miRNA-binding site in the 3' UTR of HSD3B7
td	Ghanbari et al., 2016
tr	ALS Peripheral blood cell eQTL of ALS and normal patients CYP27A1 eQTL Diekstra et al., 2012
td	ALS
td	Peripheral blood cell eQTL of ALS and normal patients
td	CYP27A1 eQTL
td	Diekstra et al., 2012
tr	AD Plasma metabolomic analysis of AD and normal patients Increased plasma GUDCA levels in patients with mild cognitive impairment or AD Mapstone et al., 2014
td	AD
td	Plasma metabolomic analysis of AD and normal patients
td	Increased plasma GUDCA levels in patients with mild cognitive impairment or AD
td	Mapstone et al., 2014
sec	Biology of bile acids Two aspects of bile acid metabolism are relevant to their role in neurodegenerative disorders, bile acids that circulate systemically and that are synthesized by neurons. Circulating bile acids are largely synthesized from cholesterol in the liver (Prawitt et al., 2011). Ingestion of food causes bile acid secretion from the gallbladder through the common bile duct to the duodenum in order to facilitate the absorption of lipids and lipid-soluble vitamins via formation of micelles. Upon reaching the ileum, bile acids are transported by specific transport proteins to the portal circulation for recycling back to the liver. The process is highly efficient with over 95% of bile acids resorbed, the remaining 5% proceeding to the colon and excreted through the stool. Enterohepatic recycling of the bile acid pool occurs about 12 times per day, thus the net flux of bile acids through primarily the portal, but also the systemic, circulation is substantial. The two primary bile acids produced by the liver in humans are cholic acid (CA) and chenodeoxycholic acid (CDCA). These primary bile acids can undergo conjugation with glycine or taurine prior to secretion in the bile to form glycocholic acid (GCA), taurocholic acid (TCA), glycochenodeoxycholic acid (GCDCA), and taurochenodeoxycholic acid (TCDCA). In the intestine, they can undergo dehydroxylation by gut bacteria to produce deoxycholic acid (DCA) and lithocholic acid (LCA). Further chemical modifications can also occur resulting in other minor species such as ursodeoxycholic acid (UDCA) (Zhang et al., 1997). Bile acids also function as signaling molecules through interaction with several receptor systems (Figure 1). They serve as ligands for the nuclear transcription factor farnesoid X receptor (FXR), which forms a heterodimeric complex with retinoid X receptor α (RXRα) that binds to an inverted repeat sequence in gene promoters (Hoeke et al., 2014). They are also agonists for a cellular receptor, the G protein-coupled bile acid receptor 1 (GPBAR1 or TGR5), to mediate signaling via the generation of cyclic adenosine monophosphate (cAMP) by adenylate cyclase, which stimulates cAMP-dependent protein kinase A (PKA) and phosphorylation of the cAMP response element binding protein (CREB) transcription factor (Hodge and Nunez, 2016; Schonewille et al., 2016). Figure 1 Despite documented neuroprotective roles in models of neurodegenerative disorders, the primary signaling pathways (TGR5 and FXR) and the potential role of endogenous bile acids have not yet been studied.
title	Biology of bile acids
p	Two aspects of bile acid metabolism are relevant to their role in neurodegenerative disorders, bile acids that circulate systemically and that are synthesized by neurons. Circulating bile acids are largely synthesized from cholesterol in the liver (Prawitt et al., 2011). Ingestion of food causes bile acid secretion from the gallbladder through the common bile duct to the duodenum in order to facilitate the absorption of lipids and lipid-soluble vitamins via formation of micelles. Upon reaching the ileum, bile acids are transported by specific transport proteins to the portal circulation for recycling back to the liver. The process is highly efficient with over 95% of bile acids resorbed, the remaining 5% proceeding to the colon and excreted through the stool. Enterohepatic recycling of the bile acid pool occurs about 12 times per day, thus the net flux of bile acids through primarily the portal, but also the systemic, circulation is substantial.
p	The two primary bile acids produced by the liver in humans are cholic acid (CA) and chenodeoxycholic acid (CDCA). These primary bile acids can undergo conjugation with glycine or taurine prior to secretion in the bile to form glycocholic acid (GCA), taurocholic acid (TCA), glycochenodeoxycholic acid (GCDCA), and taurochenodeoxycholic acid (TCDCA). In the intestine, they can undergo dehydroxylation by gut bacteria to produce deoxycholic acid (DCA) and lithocholic acid (LCA). Further chemical modifications can also occur resulting in other minor species such as ursodeoxycholic acid (UDCA) (Zhang et al., 1997).
p	Bile acids also function as signaling molecules through interaction with several receptor systems (Figure 1). They serve as ligands for the nuclear transcription factor farnesoid X receptor (FXR), which forms a heterodimeric complex with retinoid X receptor α (RXRα) that binds to an inverted repeat sequence in gene promoters (Hoeke et al., 2014). They are also agonists for a cellular receptor, the G protein-coupled bile acid receptor 1 (GPBAR1 or TGR5), to mediate signaling via the generation of cyclic adenosine monophosphate (cAMP) by adenylate cyclase, which stimulates cAMP-dependent protein kinase A (PKA) and phosphorylation of the cAMP response element binding protein (CREB) transcription factor (Hodge and Nunez, 2016; Schonewille et al., 2016).
figure	Figure 1 Despite documented neuroprotective roles in models of neurodegenerative disorders, the primary signaling pathways (TGR5 and FXR) and the potential role of endogenous bile acids have not yet been studied.
label	Figure 1
caption	Despite documented neuroprotective roles in models of neurodegenerative disorders, the primary signaling pathways (TGR5 and FXR) and the potential role of endogenous bile acids have not yet been studied.
p	Despite documented neuroprotective roles in models of neurodegenerative disorders, the primary signaling pathways (TGR5 and FXR) and the potential role of endogenous bile acids have not yet been studied.
sec	Alzheimer's disease Alzheimer's disease (AD) is characterized by dementia and memory loss that is associated with extracellular senile plaques of amyloid precursor protein derived amyloid-beta (Aβ) protein and intracellular neurofibrillary tangles consisting of the Tau protein (Scheltens et al., 2016). A primary in vitro model of AD is therefore treatment of cells with Aβ peptide that causes cytotoxicity to both primary cultures of neurons as well as neuronal cell lines. Treatment of primary cortical neuron cultures derived from Wistar rat embryos with tauroursodeoxycholic acid (TUDCA) prior to exposure to Aβ peptide significantly decreased nuclear fragmentation and cytochrome c release that was dependent upon activation of the PI3K pathway (Solá et al., 2003). The bile acid UDCA was found to regulate IκBα and NF-κB regulated genes in the mechanism of protection against Aβ toxicity in the BV-2 microglial cell line (Joo et al., 2004). Certain steroid hormones exhibit neuroprotective properties that are thought to be mediated in part through interaction with nuclear steroid receptors, including the glucocorticoid, and mineralocorticoid receptors (Garcia-Segura and Balthazart, 2009). Neurosteroids and bile acids are cholesterol derivatives that share some structural similarity so certain bile acids are natural ligands for these receptors. UDCA and TUDCA reduced Aβ induced apoptosis of primary rat cortical neurons that was found to be dependent upon the mineralocorticoid but not the glucocorticoid receptor (Sola et al., 2006). TUDCA appeared to interact with the ligand binding domain of the mineralocorticoid receptor to prevent its binding to heat shock protein 90 and subsequent trafficking for proteosomal processing allowing for translocation to the nucleus. Bile acids have also been studied in animal models of AD. In double transgenic mice (APP/PS1) that express human amyloid precursor protein carrying the KM670/671NL Swedish double mutation and the human presenilin 1 L166P mutation under the regulation of a neuron-specific promoter, treatment via dietary supplementation of standard laboratory chow with 0.4% (wt/wt) of TUDCA significantly reduced amyloid plaque number in the frontal cortex and hippocampus, decreased injury to neurons measured by determining loss of, or damage to, neuronal fibers surrounding plaques, and improved memory retention measured via contextual, though not auditory, fear conditioning (Nunes et al., 2012) as well as reduced hippocampal and prefrontal amyloid deposition (Lo et al., 2013). TUDCA has also been shown to help preserve the postsynaptic marker postsynaptic density-95 in the hippocampus of APP/PS1 mice (Ramalho et al., 2013). Repurposed RXR agonists or “rexinoids” have also shown some effectiveness in transgenic models of AD (Koster et al., 2016), suggesting a possible involvement of bile acids. In humans, a recent study of cognitively intact patients identified and validated a set of blood-based biomarkers that included glycoursodeoxycholic acid (GUDCA) that could predict the onset of either AD or amnestic mild cognitive impairment, considered an early precursor of AD, within 2–3 years with an accuracy of over 90% (Mapstone et al., 2014). This suggests a potential association of bile acids in the progression or preclinical neurodegenerative phase of AD.
title	Alzheimer's disease
p	Alzheimer's disease (AD) is characterized by dementia and memory loss that is associated with extracellular senile plaques of amyloid precursor protein derived amyloid-beta (Aβ) protein and intracellular neurofibrillary tangles consisting of the Tau protein (Scheltens et al., 2016). A primary in vitro model of AD is therefore treatment of cells with Aβ peptide that causes cytotoxicity to both primary cultures of neurons as well as neuronal cell lines. Treatment of primary cortical neuron cultures derived from Wistar rat embryos with tauroursodeoxycholic acid (TUDCA) prior to exposure to Aβ peptide significantly decreased nuclear fragmentation and cytochrome c release that was dependent upon activation of the PI3K pathway (Solá et al., 2003). The bile acid UDCA was found to regulate IκBα and NF-κB regulated genes in the mechanism of protection against Aβ toxicity in the BV-2 microglial cell line (Joo et al., 2004).
p	Certain steroid hormones exhibit neuroprotective properties that are thought to be mediated in part through interaction with nuclear steroid receptors, including the glucocorticoid, and mineralocorticoid receptors (Garcia-Segura and Balthazart, 2009). Neurosteroids and bile acids are cholesterol derivatives that share some structural similarity so certain bile acids are natural ligands for these receptors. UDCA and TUDCA reduced Aβ induced apoptosis of primary rat cortical neurons that was found to be dependent upon the mineralocorticoid but not the glucocorticoid receptor (Sola et al., 2006). TUDCA appeared to interact with the ligand binding domain of the mineralocorticoid receptor to prevent its binding to heat shock protein 90 and subsequent trafficking for proteosomal processing allowing for translocation to the nucleus.
p	Bile acids have also been studied in animal models of AD. In double transgenic mice (APP/PS1) that express human amyloid precursor protein carrying the KM670/671NL Swedish double mutation and the human presenilin 1 L166P mutation under the regulation of a neuron-specific promoter, treatment via dietary supplementation of standard laboratory chow with 0.4% (wt/wt) of TUDCA significantly reduced amyloid plaque number in the frontal cortex and hippocampus, decreased injury to neurons measured by determining loss of, or damage to, neuronal fibers surrounding plaques, and improved memory retention measured via contextual, though not auditory, fear conditioning (Nunes et al., 2012) as well as reduced hippocampal and prefrontal amyloid deposition (Lo et al., 2013). TUDCA has also been shown to help preserve the postsynaptic marker postsynaptic density-95 in the hippocampus of APP/PS1 mice (Ramalho et al., 2013). Repurposed RXR agonists or “rexinoids” have also shown some effectiveness in transgenic models of AD (Koster et al., 2016), suggesting a possible involvement of bile acids.
p	In humans, a recent study of cognitively intact patients identified and validated a set of blood-based biomarkers that included glycoursodeoxycholic acid (GUDCA) that could predict the onset of either AD or amnestic mild cognitive impairment, considered an early precursor of AD, within 2–3 years with an accuracy of over 90% (Mapstone et al., 2014). This suggests a potential association of bile acids in the progression or preclinical neurodegenerative phase of AD.
sec	Parkinson's disease The effects of bile acids on chemical and genetic models of Parkinson's disease (PD), which is characterized by the selective loss of dopaminergic neurons in the substantia nigra region of the brain and a resulting tremor, have been reported. Sodium nitroprusside (SNP)-induced cytotoxicity of human dopaminergic SH-SY5Y cells has been used as a model of PD. UDCA was found to dose-dependently (50–200 μM) decrease SNP-related cell death. UDCA reduced reactive oxygen species (ROS), reactive nitrogen species (peroxynitrite and nitric oxide), and helped to maintain intracellular glutathione (GSH) levels. Apoptosis markers including nuclear fragmentation, caspase activation, and cytochrome c release were correspondingly reduced. Inhibiting phosphatidylinositiol-3-kinase (PI3K) and Akt/PKB blocked the favorable effects of UDCA on SNP-induced cytotoxic cell death (Chun and Low, 2012). Bile acids have also been implicated in PD through genetic association studies. In a meta-analysis of genome-wide association study (GWAS) data based on the genotypes of 2,525,705 SNPs in 4238 PD cases and 4239 non-PD controls, a total of 3 SNPs were found to be statistically associated with PD, including a non-synonymous missense variant in HSD3B7 (hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7) (Song and Lee, 2013). Recessive mutations in HSD3B7, which catalyzes the second step in the classical pathway of bile acid synthesis, are associated with loss of bile acid synthetic capability and progressive liver disease (Cheng et al., 2003). In a GWAS of 48,844 SNPs residing in miRNA-binding site variants, 32 SNPs were associated with PD that were located in the 3′ untranslated regions of 13 genes including HSD3B7 (Ghanbari et al., 2016), providing further genetic evidence for a role of bile acids in PD. Mitochondrial dysfunction has been associated with PD (Luo et al., 2015). To identify compounds that could restore mitochondrial function in skin fibroblasts obtained from patients with a PD parkin (PARK2) gene mutation, a 2000 compound library was screened for significant improvement in mitochondrial membrane potential (Mortiboys et al., 2013). Ursocholanic acid and the related compound dehydro(11,12)ursolic acid lactone were among the top 15 compounds that had dose response characteristics favorable for drug development and lacked many of the disadvantages of the other top hits. The structurally related bile acid UDCA was also found to rescue mitochondrial function to a similar extent, which was dependent upon activation of the glucocorticoid receptor and increased phosphorylation of Akt. UDCA was also found to restore mitochondrial function in fibroblasts obtained from a PD patient with a LRRK2-G2019S mutation. The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin is a widely used toxin model for PD, replicating most of the clinical and pathological features of PD in humans and animal models. TUDCA was found to play a role in ameliorating neurodegeneration in MPTP-induced degeneration of dopaminergic neurons in the nigrostriatal axis in C57BL/6 glutathione S-transferase pi (GSTP) null mice (Castro-Caldas et al., 2012). Treatment of mice with TUDCA prior to MPTP caused a 30% reduction in loss of dopaminergic neurons and reduced dopaminergic fiber loss. MPTP toxicity has also been associated with increased ROS production and activation of JNK-mediated apoptosis (Huang et al., 2016). TUDCA reduced levels of ROS and preserved levels of phosphorylated JNK (p-JNK) (Castro-Caldas et al., 2012).
title	Parkinson's disease
p	The effects of bile acids on chemical and genetic models of Parkinson's disease (PD), which is characterized by the selective loss of dopaminergic neurons in the substantia nigra region of the brain and a resulting tremor, have been reported. Sodium nitroprusside (SNP)-induced cytotoxicity of human dopaminergic SH-SY5Y cells has been used as a model of PD. UDCA was found to dose-dependently (50–200 μM) decrease SNP-related cell death. UDCA reduced reactive oxygen species (ROS), reactive nitrogen species (peroxynitrite and nitric oxide), and helped to maintain intracellular glutathione (GSH) levels. Apoptosis markers including nuclear fragmentation, caspase activation, and cytochrome c release were correspondingly reduced. Inhibiting phosphatidylinositiol-3-kinase (PI3K) and Akt/PKB blocked the favorable effects of UDCA on SNP-induced cytotoxic cell death (Chun and Low, 2012).
p	Bile acids have also been implicated in PD through genetic association studies. In a meta-analysis of genome-wide association study (GWAS) data based on the genotypes of 2,525,705 SNPs in 4238 PD cases and 4239 non-PD controls, a total of 3 SNPs were found to be statistically associated with PD, including a non-synonymous missense variant in HSD3B7 (hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7) (Song and Lee, 2013). Recessive mutations in HSD3B7, which catalyzes the second step in the classical pathway of bile acid synthesis, are associated with loss of bile acid synthetic capability and progressive liver disease (Cheng et al., 2003). In a GWAS of 48,844 SNPs residing in miRNA-binding site variants, 32 SNPs were associated with PD that were located in the 3′ untranslated regions of 13 genes including HSD3B7 (Ghanbari et al., 2016), providing further genetic evidence for a role of bile acids in PD.
p	Mitochondrial dysfunction has been associated with PD (Luo et al., 2015). To identify compounds that could restore mitochondrial function in skin fibroblasts obtained from patients with a PD parkin (PARK2) gene mutation, a 2000 compound library was screened for significant improvement in mitochondrial membrane potential (Mortiboys et al., 2013). Ursocholanic acid and the related compound dehydro(11,12)ursolic acid lactone were among the top 15 compounds that had dose response characteristics favorable for drug development and lacked many of the disadvantages of the other top hits. The structurally related bile acid UDCA was also found to rescue mitochondrial function to a similar extent, which was dependent upon activation of the glucocorticoid receptor and increased phosphorylation of Akt. UDCA was also found to restore mitochondrial function in fibroblasts obtained from a PD patient with a LRRK2-G2019S mutation.
p	The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin is a widely used toxin model for PD, replicating most of the clinical and pathological features of PD in humans and animal models. TUDCA was found to play a role in ameliorating neurodegeneration in MPTP-induced degeneration of dopaminergic neurons in the nigrostriatal axis in C57BL/6 glutathione S-transferase pi (GSTP) null mice (Castro-Caldas et al., 2012). Treatment of mice with TUDCA prior to MPTP caused a 30% reduction in loss of dopaminergic neurons and reduced dopaminergic fiber loss. MPTP toxicity has also been associated with increased ROS production and activation of JNK-mediated apoptosis (Huang et al., 2016). TUDCA reduced levels of ROS and preserved levels of phosphorylated JNK (p-JNK) (Castro-Caldas et al., 2012).
sec	Amyotrophic lateral sclerosis The loss of motor neurons in Amyotrophic lateral sclerosis (ALS) has prompted therapeutic strategies aimed at preventing neuronal cell death and promoting regeneration (Carvalho et al., 2015). NSC-34 cells, created by fusion of cultured neuroblastoma cells and motor neurons from mouse spinal cord, can be treated with retinoic acid to induce neurite outgrowth and functional characteristics of motor neurons and are considered a highly stable and widely used murine motor neuron cell line model (Maier et al., 2013; Veyrat-Durebex et al., 2014). NSC-34 cells modified to carry the human form of SOD1 with the G93A mutation (hSOD1G93A) have thus been used as a model for ALS. GUDCA was reported to reduce cell death in the NSC-34 hSOD1G93A cell model and to block caspase-9 activation (Vaz et al., 2015). Bile acids also appear to have physiological roles in the central nervous system. CA, a bile acid present in the adult brain, was identified by LC/MS as a ligand of liver X receptor (LXR), activating LXR but not FXR in ventral midbrain dopaminergic neurons (Theofilopoulos et al., 2013). 6α-hydroxylated bile acids and the synthetic bile acid ligand GW3965 were also highly potent activators of LXR. Male LXR knockout mice develop an adult-onset motor neuron degeneration that is associated with impairment of motor coordination, axonal atrophy, astrogliosis, accumulation of lipid and loss of motor neurons in the spinal cord, findings similar to the neuropathology of ALS (Andersson et al., 2005). Additionally, FXR has been shown to contribute to normal motor function in mice (Huang et al., 2015). Several clinical trials of bile acids have been conducted in ALS patients in which evidence for safety and potential efficacy was observed (Parry et al., 2010; Min et al., 2012; Elia et al., 2016). In an ALS clinical trial with orally administered UDCA, the bile acid was found to be well tolerated and crossed into the cerebrospinal fluid in a dose-dependent manner (Parry et al., 2010). In a separate clinical trial to test the efficacy of UDCA for treating ALS patients, oral solubilized administration for 3 months was shown to be well tolerated and there was a slight decrease in the progression of ALS in the treatment group as compared to the placebo group (Min et al., 2012). However, due to the small size of the study and the high rate of patient dropout, the efficacy of the treatment was inconclusive. TUDCA administered orally twice per day for over 1 year resulted in a higher percentage of subjects achieving at least a 15% improvement in the ALS Functional Rating Scale Revised (ALSFRS-R) slope (Elia et al., 2016). Genetic data also implicates bile acid metabolism in ALS. Gene expression profiles obtained from the peripheral blood cells of sporadic ALS patients and normal controls were analyzed in the context of genome-wide SNP genotype data to identify expression quantitative trait loci (eQTLs). A cluster of transcript-SNP pairs with the highest level of statistical significance and meeting correction for multiple testing was associated with CYP27A1 expression in ALS (Diekstra et al., 2012). CYP27A1 is a key enzyme in the alternative bile acid synthesis pathway, and mutations in this enzyme can cause cerebrotendinous xanthomatosis as described below.
title	Amyotrophic lateral sclerosis
p	The loss of motor neurons in Amyotrophic lateral sclerosis (ALS) has prompted therapeutic strategies aimed at preventing neuronal cell death and promoting regeneration (Carvalho et al., 2015). NSC-34 cells, created by fusion of cultured neuroblastoma cells and motor neurons from mouse spinal cord, can be treated with retinoic acid to induce neurite outgrowth and functional characteristics of motor neurons and are considered a highly stable and widely used murine motor neuron cell line model (Maier et al., 2013; Veyrat-Durebex et al., 2014). NSC-34 cells modified to carry the human form of SOD1 with the G93A mutation (hSOD1G93A) have thus been used as a model for ALS. GUDCA was reported to reduce cell death in the NSC-34 hSOD1G93A cell model and to block caspase-9 activation (Vaz et al., 2015).
p	Bile acids also appear to have physiological roles in the central nervous system. CA, a bile acid present in the adult brain, was identified by LC/MS as a ligand of liver X receptor (LXR), activating LXR but not FXR in ventral midbrain dopaminergic neurons (Theofilopoulos et al., 2013). 6α-hydroxylated bile acids and the synthetic bile acid ligand GW3965 were also highly potent activators of LXR. Male LXR knockout mice develop an adult-onset motor neuron degeneration that is associated with impairment of motor coordination, axonal atrophy, astrogliosis, accumulation of lipid and loss of motor neurons in the spinal cord, findings similar to the neuropathology of ALS (Andersson et al., 2005). Additionally, FXR has been shown to contribute to normal motor function in mice (Huang et al., 2015).
p	Several clinical trials of bile acids have been conducted in ALS patients in which evidence for safety and potential efficacy was observed (Parry et al., 2010; Min et al., 2012; Elia et al., 2016). In an ALS clinical trial with orally administered UDCA, the bile acid was found to be well tolerated and crossed into the cerebrospinal fluid in a dose-dependent manner (Parry et al., 2010). In a separate clinical trial to test the efficacy of UDCA for treating ALS patients, oral solubilized administration for 3 months was shown to be well tolerated and there was a slight decrease in the progression of ALS in the treatment group as compared to the placebo group (Min et al., 2012). However, due to the small size of the study and the high rate of patient dropout, the efficacy of the treatment was inconclusive. TUDCA administered orally twice per day for over 1 year resulted in a higher percentage of subjects achieving at least a 15% improvement in the ALS Functional Rating Scale Revised (ALSFRS-R) slope (Elia et al., 2016).
p	Genetic data also implicates bile acid metabolism in ALS. Gene expression profiles obtained from the peripheral blood cells of sporadic ALS patients and normal controls were analyzed in the context of genome-wide SNP genotype data to identify expression quantitative trait loci (eQTLs). A cluster of transcript-SNP pairs with the highest level of statistical significance and meeting correction for multiple testing was associated with CYP27A1 expression in ALS (Diekstra et al., 2012). CYP27A1 is a key enzyme in the alternative bile acid synthesis pathway, and mutations in this enzyme can cause cerebrotendinous xanthomatosis as described below.
sec	Huntington's disease Huntington's disease (HD), an autosomal dominantly inherited neurodegenerative disease, is caused by an expansion mutation in CAG triplet repeat number in exon 1 of the huntingtin (HTT) gene (Ross et al., 2014). It is characterized by involuntary choreic movements, psychiatric and behavioral disturbances, and impaired cognitive function. Genetic and chemical animal and cellular models have been developed in which the effects of bile acids have been assessed. For example, 3-nitropropionic acid, an irreversible chemical inhibitor of mitochondrial succinate dehydrogenase, can be used to induce apoptosis of cells in culture and in neurons in the striatum region of the brain that causes changes similar to the morphology and neurochemical changes of HD. Incubation of rat neuronal RN33B cells with TUDCA was found to reduce 3-nitropropionic acid induced apoptosis by about 80% (Rodrigues et al., 2000). Other bile acids, including UDCA and GUDCA, were also associated with decreased apoptosis, preventing 3-nitropropionic acid induced release of mitochondrial cytochrome c, and associated morphological changes in both isolated mitochondria and in intact cells. In rats treated with TUDCA, a similar level of reduction in apoptosis and in the volume of lesions associated with administration of 3-nitropropionic acid was observed that was correlated with preservation of sensorimotor function and performance in cognitive task assays (Keene et al., 2001). These results suggest that the mechanisms of bile acid protection may be similar both in vitro and in vivo. Genetic models of HD have also been studied, including the R6/2 mouse, which is transgenic for a 150 repeat trinucleotide CAG expansion in exon 1 of HTT and manifests severe neurodegeneration, neuronal intranuclear inclusions, and sensorimotor deficits that result in a severely shortened survival of less than 4 months of age (Mangiarini et al., 1996; Davies et al., 1997). TUDCA treatment was administered to the R6/2 transgenic mice subcutaneously at a dose of 500 mg/kg once every 3 days from weaning to 6 months of age, which was tolerated without skin reaction or other effects. The subcutaneously administered TUDCA was absorbed into the circulation, crossed the blood-brain barrier, and produced seven-fold increases in UDCA levels in the brain without evidence of adverse effects. TUDCA treatment resulted in significantly reduced striatal cell apoptosis, decreased levels of intracellular inclusions, and improved locomotor open field and sensorimotor Rota-Rod performances (Keene et al., 2002).
title	Huntington's disease
p	Huntington's disease (HD), an autosomal dominantly inherited neurodegenerative disease, is caused by an expansion mutation in CAG triplet repeat number in exon 1 of the huntingtin (HTT) gene (Ross et al., 2014). It is characterized by involuntary choreic movements, psychiatric and behavioral disturbances, and impaired cognitive function. Genetic and chemical animal and cellular models have been developed in which the effects of bile acids have been assessed. For example, 3-nitropropionic acid, an irreversible chemical inhibitor of mitochondrial succinate dehydrogenase, can be used to induce apoptosis of cells in culture and in neurons in the striatum region of the brain that causes changes similar to the morphology and neurochemical changes of HD. Incubation of rat neuronal RN33B cells with TUDCA was found to reduce 3-nitropropionic acid induced apoptosis by about 80% (Rodrigues et al., 2000). Other bile acids, including UDCA and GUDCA, were also associated with decreased apoptosis, preventing 3-nitropropionic acid induced release of mitochondrial cytochrome c, and associated morphological changes in both isolated mitochondria and in intact cells. In rats treated with TUDCA, a similar level of reduction in apoptosis and in the volume of lesions associated with administration of 3-nitropropionic acid was observed that was correlated with preservation of sensorimotor function and performance in cognitive task assays (Keene et al., 2001). These results suggest that the mechanisms of bile acid protection may be similar both in vitro and in vivo.
p	Genetic models of HD have also been studied, including the R6/2 mouse, which is transgenic for a 150 repeat trinucleotide CAG expansion in exon 1 of HTT and manifests severe neurodegeneration, neuronal intranuclear inclusions, and sensorimotor deficits that result in a severely shortened survival of less than 4 months of age (Mangiarini et al., 1996; Davies et al., 1997). TUDCA treatment was administered to the R6/2 transgenic mice subcutaneously at a dose of 500 mg/kg once every 3 days from weaning to 6 months of age, which was tolerated without skin reaction or other effects. The subcutaneously administered TUDCA was absorbed into the circulation, crossed the blood-brain barrier, and produced seven-fold increases in UDCA levels in the brain without evidence of adverse effects. TUDCA treatment resulted in significantly reduced striatal cell apoptosis, decreased levels of intracellular inclusions, and improved locomotor open field and sensorimotor Rota-Rod performances (Keene et al., 2002).
sec	Spinocerebellar ataxia type 1 Spinocerebellar ataxia type 1 (SCA1) is another dominantly inherited neurodegenerative disorder characterized chiefly by progressive ataxia (Meera et al., 2016). SCA1 is caused by expansion of an unstable CAG trinucleotide repeat that encodes a glutamine tract in the Ataxin-1 gene (ATXN1). The disorder is characterized primarily by degeneration of Purkinje neurons of the cerebellum. TUDCA treatment was used to determine whether the survival of Purkinje cells and the onset and progression of ataxia was altered in a transgenic mouse model of SCA1, in which 30 copies of the human ATXN1 cDNA containing a CAG trinucleotide repeat of 82 repeats was under the control of the Pcp-2 Purkinje-cell specific promoter l (Kaemmerer et al., 2001). Despite the successful administration of TUDCA using a similar subcutaneous injection protocol as described above for the R6/2 transgenic HD mouse, and documentation of increased levels in the brain, no effects on cell survival or on the neurological phenotype were noted. The disparate effects in two different genetic models of neurodegenerative disease, suggest that bile acids target specific pathways.
title	Spinocerebellar ataxia type 1
p	Spinocerebellar ataxia type 1 (SCA1) is another dominantly inherited neurodegenerative disorder characterized chiefly by progressive ataxia (Meera et al., 2016). SCA1 is caused by expansion of an unstable CAG trinucleotide repeat that encodes a glutamine tract in the Ataxin-1 gene (ATXN1). The disorder is characterized primarily by degeneration of Purkinje neurons of the cerebellum. TUDCA treatment was used to determine whether the survival of Purkinje cells and the onset and progression of ataxia was altered in a transgenic mouse model of SCA1, in which 30 copies of the human ATXN1 cDNA containing a CAG trinucleotide repeat of 82 repeats was under the control of the Pcp-2 Purkinje-cell specific promoter l (Kaemmerer et al., 2001). Despite the successful administration of TUDCA using a similar subcutaneous injection protocol as described above for the R6/2 transgenic HD mouse, and documentation of increased levels in the brain, no effects on cell survival or on the neurological phenotype were noted. The disparate effects in two different genetic models of neurodegenerative disease, suggest that bile acids target specific pathways.
sec	Prion diseases Neurodegenerative disorders caused by prions include Creutzfeldt-Jakob disease and similar disorders in animals such as bovine spongiform encephalopathy in cows, chronic wasting disease in deer, and scrapie in sheep (Imran and Mahmood, 2011; Windl and Dawson, 2012). Prion protein (PrPC) is a normal cellular protein that when mutated becomes misfolded (PrPSc). PrPSc can then convert normally folded PrPC to the misfolded form. Accumulation of PrPSc causes loss of neurons, astrogliosis, and spongiform degeneration resulting in dementia, ataxia, and death. One approach to therapeutic development has been to block or interfere with the conversion of PrPC to PrPSc. TUDCA and UDCA were found to substantially reduce this conversion in cell-free aggregation assays as well as in both chronically and acutely infected mouse ScN2a neuroblastoma cells (Cortez et al., 2015). TUDCA and UDCA also reduced neuronal loss in a prion organotypic slice culture model of intracerebral infection that assesses prion replication occurring ex vivo through infection of brain slices with prion infected brain homogenate. UDCA treatment also reduced astrocytosis and prolonged survival in prion infected male C57BL/6 mice, although whether bile acids interacted with the PrPC to PrPSc conversion or mediated protective effects through some other mechanism is not known.
title	Prion diseases
p	Neurodegenerative disorders caused by prions include Creutzfeldt-Jakob disease and similar disorders in animals such as bovine spongiform encephalopathy in cows, chronic wasting disease in deer, and scrapie in sheep (Imran and Mahmood, 2011; Windl and Dawson, 2012). Prion protein (PrPC) is a normal cellular protein that when mutated becomes misfolded (PrPSc). PrPSc can then convert normally folded PrPC to the misfolded form. Accumulation of PrPSc causes loss of neurons, astrogliosis, and spongiform degeneration resulting in dementia, ataxia, and death. One approach to therapeutic development has been to block or interfere with the conversion of PrPC to PrPSc. TUDCA and UDCA were found to substantially reduce this conversion in cell-free aggregation assays as well as in both chronically and acutely infected mouse ScN2a neuroblastoma cells (Cortez et al., 2015). TUDCA and UDCA also reduced neuronal loss in a prion organotypic slice culture model of intracerebral infection that assesses prion replication occurring ex vivo through infection of brain slices with prion infected brain homogenate. UDCA treatment also reduced astrocytosis and prolonged survival in prion infected male C57BL/6 mice, although whether bile acids interacted with the PrPC to PrPSc conversion or mediated protective effects through some other mechanism is not known.
sec	Cerebrotendinous xanthomatosis Cerebrotendinous xanthomatosis (CTX) is a very rare autosomal recessive disorder caused by mutations in the CYP27A1 gene (Björkhem and Hansson, 2010; Bjorkhem, 2013). These mutations lead to deficiency of the sterol 27-hydroxylase inner mitochondrial membrane protein. Sterol 27-hydroxylase oxidizes cholesterol to 27-hydroxycholesterol in the alternative bile acid synthesis pathway that leads to the generation of CDCA. Sterol 27-hydroxylase deficiency leads to a reduction of CDCA and upregulation of cholesterol 7α-hydroxylase (CYP7A1), the rate-limiting enzyme in the classic bile acid synthesis pathway resulting in elevated levels of cholestanol and bile alcohols. CTX patients have a mean age of diagnosis of 35 years and manifest multiple neurologic symptoms including dementia, ataxia, peripheral neuropathy, epilepsy, myopathy, and psychiatric disorders, as well as a variety of non-neurological manifestations including premature atherosclerosis, tendon xanthomas, juvenile onset cataracts, osteoporosis, and mild pulmonary insufficiency. Long-term treatment with CDCA can result in amelioration of neurological symptoms and an improved prognosis.
title	Cerebrotendinous xanthomatosis
p	Cerebrotendinous xanthomatosis (CTX) is a very rare autosomal recessive disorder caused by mutations in the CYP27A1 gene (Björkhem and Hansson, 2010; Bjorkhem, 2013). These mutations lead to deficiency of the sterol 27-hydroxylase inner mitochondrial membrane protein. Sterol 27-hydroxylase oxidizes cholesterol to 27-hydroxycholesterol in the alternative bile acid synthesis pathway that leads to the generation of CDCA. Sterol 27-hydroxylase deficiency leads to a reduction of CDCA and upregulation of cholesterol 7α-hydroxylase (CYP7A1), the rate-limiting enzyme in the classic bile acid synthesis pathway resulting in elevated levels of cholestanol and bile alcohols. CTX patients have a mean age of diagnosis of 35 years and manifest multiple neurologic symptoms including dementia, ataxia, peripheral neuropathy, epilepsy, myopathy, and psychiatric disorders, as well as a variety of non-neurological manifestations including premature atherosclerosis, tendon xanthomas, juvenile onset cataracts, osteoporosis, and mild pulmonary insufficiency. Long-term treatment with CDCA can result in amelioration of neurological symptoms and an improved prognosis.
sec	Retinal diseases Bear bile has been used in Chinese medicine for several millennia to treat visual disorders (Boatright et al., 2006). This has led to a number of studies investigating the primary constituent of bear bile, TUDCA, as a potential therapeutic agent for several ophthalmological diseases (Boatright et al., 2009). TUDCA has been investigated in retinitis pigmentosa, a heterogeneous group of disorders of retinal degeneration in which progressive peripheral and night vision loss occurs, with central vision impairment. Mutations in about 200 genes, including the gene encoding rhodopsin (RHO), have been identified that cause apoptosis of photoreceptor cells (Daiger et al., 2013). The RHO P23H mutation is the most common cause of retinitis pigmentosa in the United States that is thought to produce structurally altered folding with retention in the endoplasmic reticulum and resulting cytotoxicity. TUDCA administered intraperitoneally once a week from weaning until 4 months of age to homozygous P23H line-3 rats reduced photoreceptor loss across the retina and preserved synapses between photoreceptors and bipolar or horizontal cells (Fernandez-Sanchez et al., 2011). In the rd10 mouse model of retinitis pigmentosa, in which the mice carry a missense mutation in exon 7 of the Pde6b gene resulting in rod photoreceptor cell death within a month after birth, subcutaneous administration of TUDCA resulted in higher cone cell density in all 4 quadrants of the retina (Oveson et al., 2011). TUDCA also decreased apoptosis, preserved the normal retinal photoreceptor cellular architecture, and maintained amplitudes of dark-adapted electroretinogram a- and b-waves (Boatright et al., 2006), even at later stages of severe photoreceptor loss (Phillips et al., 2008). Mutations in the retinoid isomerase (RPE65) or lecithin-retinol acyltransferase (LRAT) genes underlie Leber congenital amaurosis (den Hollander et al., 2008). LRAT is involved in 11-cis retinal recycling in the retinal pigment epithelium through mediating the esterification of all-trans retinol to all-trans retinyl esters, which are the substrates for RPE65. Homozygous Lrat knockout mice that were subcutaneously administered TUDCA every 3 days from 1 to 4 weeks after birth had about a three-fold increase in cone density in the ventral and central retina and increased ER-associated protein degradation (Zhang et al., 2012; Fu and Zhang, 2014). Twice per week subcutaneous injections of TUDCA also preserved ERG b-waves and the outer nuclear layer of the retina in Bardet-Biedl syndrome type 1 mice (Bbs1M390R/M390R), another model for retinal degeneration (Drack et al., 2012). TUDCA ameliorated cell death and loss of photoreceptor function after exposure to high levels of light (10,000 lux) that can induce retinal degeneration in albino Balb/C mice (Boatright et al., 2006). TUDCA pre-treatment of ex vivo perfused whole mount feline retinas repeatedly exposed to light stimulation and dark adaptations over 5 h resulted in greater receptive field size, decreased irradiance threshold, and maintenance of the contrast threshold (Xia et al., 2015). Retinal dystrophy can be caused by defects in the phagocytosis by retinal pigment epithelium cells of the photoreceptor outer segments that are shed, a continuous and extremely active process involving thousands of shed membranous disks each day. TUDCA was found to increase phagocytic activity and inhibit hydrogen peroxide induced impairment of phagocytosis by both cultured ARPE-19 cells and primary human retinal pigment epithelium cells (Murase et al., 2015). The phosphorylation of MerTK was significantly increased by TUDCA in a concentration-dependent manner but did not affect expression of the ER stress marker glucose regulated protein-78 (GRP-78). Bile acids also had an effect in ameliorating cell death in a model of retinal detachment via intraperitoneal injection of TUDCA at 3 and 5 days post detachment, times when acute photoreceptor loss occurs in the outer nuclear layer of the retina (Mantopoulos et al., 2011). TUDCA treatment also blocked the production of protein carbonyls with decreased caspase activation but did not decrease endoplasmic reticulum (ER) stress. In a diabetic retinopathy model, TUDCA significantly decreased apoptosis measured by TUNEL assay of primary rat retinal neural cells exposed to 30 mM glucose concentration, which causes caspase-independent cell death (Gaspar et al., 2013). TUDCA also decreased the amount of apoptosis-inducing factor (AIF) released from the mitochondria and its subsequent accumulation in the nucleus. Production of protein carbonyls and ROS were also significantly decreased after TUDCA treatment. Over-stimulation of N-methyl-D-aspartate (NMDA) receptors, one of three ionotropic glutamate receptor subtypes that are expressed in inner retinal cells, by intravitreal injection of NMDA has frequently been used to model the cell death pathway that occurs in retinal diseases such as glaucoma (Danesh-Meyer, 2011). This model of excitotoxicity causes disruption of sodium-potassium balance, calcium overload, mitochondrial dysfunction, and oxidative stress (Gomez-Vicente et al., 2015). In mice, administration of TUDCA prior to the intravitreal injection of NMDA was found to increase survival of retinal ganglion cells.
title	Retinal diseases
p	Bear bile has been used in Chinese medicine for several millennia to treat visual disorders (Boatright et al., 2006). This has led to a number of studies investigating the primary constituent of bear bile, TUDCA, as a potential therapeutic agent for several ophthalmological diseases (Boatright et al., 2009). TUDCA has been investigated in retinitis pigmentosa, a heterogeneous group of disorders of retinal degeneration in which progressive peripheral and night vision loss occurs, with central vision impairment. Mutations in about 200 genes, including the gene encoding rhodopsin (RHO), have been identified that cause apoptosis of photoreceptor cells (Daiger et al., 2013). The RHO P23H mutation is the most common cause of retinitis pigmentosa in the United States that is thought to produce structurally altered folding with retention in the endoplasmic reticulum and resulting cytotoxicity. TUDCA administered intraperitoneally once a week from weaning until 4 months of age to homozygous P23H line-3 rats reduced photoreceptor loss across the retina and preserved synapses between photoreceptors and bipolar or horizontal cells (Fernandez-Sanchez et al., 2011). In the rd10 mouse model of retinitis pigmentosa, in which the mice carry a missense mutation in exon 7 of the Pde6b gene resulting in rod photoreceptor cell death within a month after birth, subcutaneous administration of TUDCA resulted in higher cone cell density in all 4 quadrants of the retina (Oveson et al., 2011). TUDCA also decreased apoptosis, preserved the normal retinal photoreceptor cellular architecture, and maintained amplitudes of dark-adapted electroretinogram a- and b-waves (Boatright et al., 2006), even at later stages of severe photoreceptor loss (Phillips et al., 2008).
p	Mutations in the retinoid isomerase (RPE65) or lecithin-retinol acyltransferase (LRAT) genes underlie Leber congenital amaurosis (den Hollander et al., 2008). LRAT is involved in 11-cis retinal recycling in the retinal pigment epithelium through mediating the esterification of all-trans retinol to all-trans retinyl esters, which are the substrates for RPE65. Homozygous Lrat knockout mice that were subcutaneously administered TUDCA every 3 days from 1 to 4 weeks after birth had about a three-fold increase in cone density in the ventral and central retina and increased ER-associated protein degradation (Zhang et al., 2012; Fu and Zhang, 2014). Twice per week subcutaneous injections of TUDCA also preserved ERG b-waves and the outer nuclear layer of the retina in Bardet-Biedl syndrome type 1 mice (Bbs1M390R/M390R), another model for retinal degeneration (Drack et al., 2012).
p	TUDCA ameliorated cell death and loss of photoreceptor function after exposure to high levels of light (10,000 lux) that can induce retinal degeneration in albino Balb/C mice (Boatright et al., 2006). TUDCA pre-treatment of ex vivo perfused whole mount feline retinas repeatedly exposed to light stimulation and dark adaptations over 5 h resulted in greater receptive field size, decreased irradiance threshold, and maintenance of the contrast threshold (Xia et al., 2015). Retinal dystrophy can be caused by defects in the phagocytosis by retinal pigment epithelium cells of the photoreceptor outer segments that are shed, a continuous and extremely active process involving thousands of shed membranous disks each day. TUDCA was found to increase phagocytic activity and inhibit hydrogen peroxide induced impairment of phagocytosis by both cultured ARPE-19 cells and primary human retinal pigment epithelium cells (Murase et al., 2015). The phosphorylation of MerTK was significantly increased by TUDCA in a concentration-dependent manner but did not affect expression of the ER stress marker glucose regulated protein-78 (GRP-78).
p	Bile acids also had an effect in ameliorating cell death in a model of retinal detachment via intraperitoneal injection of TUDCA at 3 and 5 days post detachment, times when acute photoreceptor loss occurs in the outer nuclear layer of the retina (Mantopoulos et al., 2011). TUDCA treatment also blocked the production of protein carbonyls with decreased caspase activation but did not decrease endoplasmic reticulum (ER) stress. In a diabetic retinopathy model, TUDCA significantly decreased apoptosis measured by TUNEL assay of primary rat retinal neural cells exposed to 30 mM glucose concentration, which causes caspase-independent cell death (Gaspar et al., 2013). TUDCA also decreased the amount of apoptosis-inducing factor (AIF) released from the mitochondria and its subsequent accumulation in the nucleus. Production of protein carbonyls and ROS were also significantly decreased after TUDCA treatment.
p	Over-stimulation of N-methyl-D-aspartate (NMDA) receptors, one of three ionotropic glutamate receptor subtypes that are expressed in inner retinal cells, by intravitreal injection of NMDA has frequently been used to model the cell death pathway that occurs in retinal diseases such as glaucoma (Danesh-Meyer, 2011). This model of excitotoxicity causes disruption of sodium-potassium balance, calcium overload, mitochondrial dysfunction, and oxidative stress (Gomez-Vicente et al., 2015). In mice, administration of TUDCA prior to the intravitreal injection of NMDA was found to increase survival of retinal ganglion cells.
sec	Acute stroke, spinal cord injury, and neuropathy A single intravenous (i.v.) dose of TUDCA administered to rats 60 min after occlusion of the middle cerebral artery markedly reduced infarct size and apoptosis and preserved mitochondrial integrity (Rodrigues et al., 2002). The single i.v. dose resulted in a significant increase in brain UDCA levels from near undetectable levels to 0.15 nmol/g. TUDCA was also found to have an anti-inflammatory effect in the context of the central nervous system. TUDCA reduced glial cell activation and microglial chemotaxis and reduced expression of the MCP-1 chemoattractant and vascular adhesion proteins such as VCAM-1 in microglial cells and astrocytes treated with either interferon gamma (IFN-γ) or lipopolysaccharide and IFN-γ (Yanguas-Casás et al., 2014). Injection of TUDCA into the carotid artery 1 h prior to or up to 6 h after collagenase injection into the striatum to induce hemorrhagic lesions decreased lesion volumes, peri-hematoma apoptosis, and caspase activity at 2 days by about 50%, as well as decreased NF-κB and increased AKT activation that was associated with neurobehavioral improvement (Rodrigues et al., 2003). TUDCA injected intraperitoneally 1 min after spinal cord crush injury decreased apoptosis and corresponding tissue injury (Colak et al., 2008). In a phase II open-label study of oral doxycycline and TUDCA taken three times/day for 1 year in patients with transthyretin amyloidosis (ATTR), progression of neuropathy was stabilized (Obici et al., 2012).
title	Acute stroke, spinal cord injury, and neuropathy
p	A single intravenous (i.v.) dose of TUDCA administered to rats 60 min after occlusion of the middle cerebral artery markedly reduced infarct size and apoptosis and preserved mitochondrial integrity (Rodrigues et al., 2002). The single i.v. dose resulted in a significant increase in brain UDCA levels from near undetectable levels to 0.15 nmol/g. TUDCA was also found to have an anti-inflammatory effect in the context of the central nervous system. TUDCA reduced glial cell activation and microglial chemotaxis and reduced expression of the MCP-1 chemoattractant and vascular adhesion proteins such as VCAM-1 in microglial cells and astrocytes treated with either interferon gamma (IFN-γ) or lipopolysaccharide and IFN-γ (Yanguas-Casás et al., 2014). Injection of TUDCA into the carotid artery 1 h prior to or up to 6 h after collagenase injection into the striatum to induce hemorrhagic lesions decreased lesion volumes, peri-hematoma apoptosis, and caspase activity at 2 days by about 50%, as well as decreased NF-κB and increased AKT activation that was associated with neurobehavioral improvement (Rodrigues et al., 2003). TUDCA injected intraperitoneally 1 min after spinal cord crush injury decreased apoptosis and corresponding tissue injury (Colak et al., 2008). In a phase II open-label study of oral doxycycline and TUDCA taken three times/day for 1 year in patients with transthyretin amyloidosis (ATTR), progression of neuropathy was stabilized (Obici et al., 2012).
sec	Modulation of neurotransmitter activity The wake period of normal mice was found to be increased with administration of UDCA that also decreased slow wave sleep (Yanovsky et al., 2012). In contrast, administration of UDCA to histidine decarboxylase knockout mice, that are deficient in histamine that stimulates arousal, decreased wakefulness and altered cortical EEG and sleep-wake parameters. Using in vitro patch-clamp recordings from histaminergic neurons, UDCA was found to inhibit GABAergic currents and to serve as an antagonist for GABAA receptors expressed in HEK293 cells. In one of the few studies to analyze more than one or two bile acids, a structure-function relationship analysis was performed using cultured hypothalamic neurons (Schubring et al., 2012). Bile acids were found to modulate firing frequency and synchrony, and to block activity of GABAA and NMDA receptors. Antagonist activity for both the GABAA and NMDA receptors was strongest for CDCA followed by DCA, CA, and dehydrocholate. Involvement of bile acid binding to TGR5 was excluded as a potential mechanism in the neurotransmitter receptor blockade (Keitel et al., 2010). CA was found to serve as an inhibiter for N-type Ca2+ channel currents of neurons isolated from the caudal paravertebral sympathetic ganglia of adult bull frogs (Rana catesbeiana), although open and shut times, slope conductance, and single channel current amplitude, were not significantly affected (Lee et al., 2012). Overstimulation of glutamate receptors to induce excitotoxicity in neurons isolated from late stage fetal rat brains was largely suppressed by GUDCA. This bile acid appeared to suppress glutamate release in either normal or microglia-depleted hippocampal tissue slices (Silva et al., 2012). Pretreatment of primary cultures of fetal rat cortical neurons with TUDCA significantly reduced glutamate excitotoxicity associated cell death. TUDCA treatment resulted in phosphorylation and translocation of the pro-apoptotic Bad protein from the mitochondria to the cytosol. Inhibiting the PI3K signaling pathway blocked the anti-apoptotic effects of TUDCA (Castro et al., 2004).
title	Modulation of neurotransmitter activity
p	The wake period of normal mice was found to be increased with administration of UDCA that also decreased slow wave sleep (Yanovsky et al., 2012). In contrast, administration of UDCA to histidine decarboxylase knockout mice, that are deficient in histamine that stimulates arousal, decreased wakefulness and altered cortical EEG and sleep-wake parameters. Using in vitro patch-clamp recordings from histaminergic neurons, UDCA was found to inhibit GABAergic currents and to serve as an antagonist for GABAA receptors expressed in HEK293 cells. In one of the few studies to analyze more than one or two bile acids, a structure-function relationship analysis was performed using cultured hypothalamic neurons (Schubring et al., 2012). Bile acids were found to modulate firing frequency and synchrony, and to block activity of GABAA and NMDA receptors. Antagonist activity for both the GABAA and NMDA receptors was strongest for CDCA followed by DCA, CA, and dehydrocholate. Involvement of bile acid binding to TGR5 was excluded as a potential mechanism in the neurotransmitter receptor blockade (Keitel et al., 2010).
p	CA was found to serve as an inhibiter for N-type Ca2+ channel currents of neurons isolated from the caudal paravertebral sympathetic ganglia of adult bull frogs (Rana catesbeiana), although open and shut times, slope conductance, and single channel current amplitude, were not significantly affected (Lee et al., 2012). Overstimulation of glutamate receptors to induce excitotoxicity in neurons isolated from late stage fetal rat brains was largely suppressed by GUDCA. This bile acid appeared to suppress glutamate release in either normal or microglia-depleted hippocampal tissue slices (Silva et al., 2012). Pretreatment of primary cultures of fetal rat cortical neurons with TUDCA significantly reduced glutamate excitotoxicity associated cell death. TUDCA treatment resulted in phosphorylation and translocation of the pro-apoptotic Bad protein from the mitochondria to the cytosol. Inhibiting the PI3K signaling pathway blocked the anti-apoptotic effects of TUDCA (Castro et al., 2004).
sec	Potential as neurotrophic factors Neurotrophic factors are classified primarily as proteins that bind to receptors, e.g., tropomyosin related kinase receptors TrkA, TrkB, and TrkC and p75 neurotrophin receptor (p75NTR) that can modulate Trk activation, to activate signaling pathways that promote neuronal growth and survival (Rodrigues et al., 2014). Several molecules have been identified as neurotrophic factors, including brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), and glial cell-line-derived neurotrophic factor (GDNF) that can stimulate the growth and differentiation of neuronal cells, as well as prevent cell death. Despite the therapeutic promise of such neurotrophic factors for treating neurodegenerative disorders (Tovar-Y-Romo et al., 2014), their limited bioavailability presents a major roadblock. Mimetics with more favorable bioavailability profiles have therefore been pursued (Tiwari and Chaturvedi, 2014), as well as investigation of proneurogenic peptides and small molecules that exhibit neuroprotective properties (Airavaara et al., 2012), including retinoic acid (Malik et al., 2000; Riancho et al., 2016). Retinoic acid shares a common role in regulating lipid homeostasis with bile acids, whose cognate receptor FXR can form heterodimers with RXRα. Thus, retinoic acid may activate the FXR signaling pathway and vice versa (Yang et al., 2014). Whether bile acids mediate effects in the nervous system through a similar mechanism is not known (Figure 1).
title	Potential as neurotrophic factors
p	Neurotrophic factors are classified primarily as proteins that bind to receptors, e.g., tropomyosin related kinase receptors TrkA, TrkB, and TrkC and p75 neurotrophin receptor (p75NTR) that can modulate Trk activation, to activate signaling pathways that promote neuronal growth and survival (Rodrigues et al., 2014). Several molecules have been identified as neurotrophic factors, including brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), and glial cell-line-derived neurotrophic factor (GDNF) that can stimulate the growth and differentiation of neuronal cells, as well as prevent cell death. Despite the therapeutic promise of such neurotrophic factors for treating neurodegenerative disorders (Tovar-Y-Romo et al., 2014), their limited bioavailability presents a major roadblock. Mimetics with more favorable bioavailability profiles have therefore been pursued (Tiwari and Chaturvedi, 2014), as well as investigation of proneurogenic peptides and small molecules that exhibit neuroprotective properties (Airavaara et al., 2012), including retinoic acid (Malik et al., 2000; Riancho et al., 2016). Retinoic acid shares a common role in regulating lipid homeostasis with bile acids, whose cognate receptor FXR can form heterodimers with RXRα. Thus, retinoic acid may activate the FXR signaling pathway and vice versa (Yang et al., 2014). Whether bile acids mediate effects in the nervous system through a similar mechanism is not known (Figure 1).
sec	Conclusions and outlook Neuroprotective effects of several bile acids are well documented in a wide range of neurodegenerative diseases, including AD, PD, ALS, HD, and retinal degeneration, in cellular and animal models and in human clinical trials. Due to the historical precedent set by the use of bear bile in ancient Chinese medicine, the majority of the studies have focused on UDCA and its derivatives. However, bile acids are a relatively large group of structurally related molecules, thus little is known about the potential efficacy of other bile acid species or the roles of circulating vs. endogenous bile acids synthesized within the central nervous system. In addition, most of the mechanistic studies have been centered on apoptosis and related pathways (Figure 2). However, essentially no data is available on the primary signaling pathways through which bile acids act, the cellular receptor TGR5 and the nuclear receptors FXR and RXRα, despite the well-known function of retinoic acid as a potent neurotrophic molecule. Determining the precise molecular mechanism(s) of neuroprotection by bile acids in neurodegenerative disorders will be important to realize their future therapeutic potential. Figure 2 Molecular pathways implicated in the neuroprotective effects of bile acids in neurodegenerative disease models. Despite the relatively large structurally related group of bile acids, relatively few have been studied in neurodegenerative disorders. A major focus has been on apoptotic pathways and the PI3 kinase and AKT signaling pathway. Surprisingly, the primary signaling pathways through which bile acids act, TGR5, FXR, and FXR/RXR have received essentially no attention (designated by “?”), despite that retinoic acid is known to be a potent neurotrophic molecule.
title	Conclusions and outlook
p	Neuroprotective effects of several bile acids are well documented in a wide range of neurodegenerative diseases, including AD, PD, ALS, HD, and retinal degeneration, in cellular and animal models and in human clinical trials. Due to the historical precedent set by the use of bear bile in ancient Chinese medicine, the majority of the studies have focused on UDCA and its derivatives. However, bile acids are a relatively large group of structurally related molecules, thus little is known about the potential efficacy of other bile acid species or the roles of circulating vs. endogenous bile acids synthesized within the central nervous system. In addition, most of the mechanistic studies have been centered on apoptosis and related pathways (Figure 2). However, essentially no data is available on the primary signaling pathways through which bile acids act, the cellular receptor TGR5 and the nuclear receptors FXR and RXRα, despite the well-known function of retinoic acid as a potent neurotrophic molecule. Determining the precise molecular mechanism(s) of neuroprotection by bile acids in neurodegenerative disorders will be important to realize their future therapeutic potential.
figure	Figure 2 Molecular pathways implicated in the neuroprotective effects of bile acids in neurodegenerative disease models. Despite the relatively large structurally related group of bile acids, relatively few have been studied in neurodegenerative disorders. A major focus has been on apoptotic pathways and the PI3 kinase and AKT signaling pathway. Surprisingly, the primary signaling pathways through which bile acids act, TGR5, FXR, and FXR/RXR have received essentially no attention (designated by “?”), despite that retinoic acid is known to be a potent neurotrophic molecule.
label	Figure 2
caption	Molecular pathways implicated in the neuroprotective effects of bile acids in neurodegenerative disease models. Despite the relatively large structurally related group of bile acids, relatively few have been studied in neurodegenerative disorders. A major focus has been on apoptotic pathways and the PI3 kinase and AKT signaling pathway. Surprisingly, the primary signaling pathways through which bile acids act, TGR5, FXR, and FXR/RXR have received essentially no attention (designated by “?”), despite that retinoic acid is known to be a potent neurotrophic molecule.
p	Molecular pathways implicated in the neuroprotective effects of bile acids in neurodegenerative disease models. Despite the relatively large structurally related group of bile acids, relatively few have been studied in neurodegenerative disorders. A major focus has been on apoptotic pathways and the PI3 kinase and AKT signaling pathway. Surprisingly, the primary signaling pathways through which bile acids act, TGR5, FXR, and FXR/RXR have received essentially no attention (designated by “?”), despite that retinoic acid is known to be a potent neurotrophic molecule.
sec	Author contributions GG and HA designed, wrote, revised, and edited the manuscript. Both authors approved the submitted version of the manuscript.
title	Author contributions
p	GG and HA designed, wrote, revised, and edited the manuscript. Both authors approved the submitted version of the manuscript.
sec	Funding This work was funded by the Lewis Katz School of Medicine at Temple University Department of Medical Genetics and Molecular Biochemistry and the Joseph & Rebecca Goodfriend Endowed Chair in Genetics. Conflict of interest statement The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
title	Funding
p	This work was funded by the Lewis Katz School of Medicine at Temple University Department of Medical Genetics and Molecular Biochemistry and the Joseph & Rebecca Goodfriend Endowed Chair in Genetics.
sec	Conflict of interest statement The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
title	Conflict of interest statement
p	The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

projects that have annotations to this span

There is no project

TAB JSON ListView MergeView

PMC:5118426 / 7466-7470 JSONTXT

Document structure show

projects that have annotations to this span

PMC:5118426 / 7466-7470 JSON TXT